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Mammalian cells are constantly at risk of damage to their DNA from 
multiple sources, including ultraviolet light, ionizing radiation (IR) and reactive 
oxygen species. Approximately 1X104 DNA lesions are generated in a 
metabolically active cell each day, the majority of which are DNA single-
strand breaks (SSBs), although included are the highly cytotoxic DNA 
double-strand breaks (DSBs). In higher eukaryotes, genomic stability is 
absolutely essential for healthy functioning and survival since DNA damage 
may induce mutations and lead to cell death. Conse quently, eukaryotic cells 
have evolved a number of mechanisms to monitor the integrity of their 
genome and repair any damaged DNA before cell cycle progression in a 
coordinated process that utilizes ‘checkpoint’ control. 
CHK2 is a versatile and multifunctional kinase that regulates the cell’s 
response to DNA damage by phosphorylating a number of distinct cellular 
substrates. As such, it might prevent tumour progression by averting genomic 
instability through DNA repair and, if this is not possible, by causing the cell 
to senesce or die. This correlates with human genetic studies clearly showing 
that CHEK2 is a multiorgan tumour susceptibility gene. 
As a unique member of the Inhibitor of Apoptosis (IAP) gene family, 
survivin has attracted attention for its multiple roles in cell proliferation and 
cell death, and its abundan distribution in every human tumor, compared to 
normal tissues. Disparate oncogenic pathways control the differential 
expression of survivin in cancer, and influence its localization to multiple 
subcellular compartments. Accordingly, transcription of the survivin locus is 
complex, giving rise to at least five mRNA species that encode, in addition to 
wild type (WT) survivin, the variants survivin-2B, -3β, -2α and -∆Ex-3. 
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Structurally, survivin-2α and -3B are generated by “read-through” into intron 
2, or via inclusion of an alternative exon 3B, whereas survivin-2B and -∆Ex3 
originate from the insertion of an alternative exon 2B , or the skipping of exon 
3, respectively. 
Elucidating the function(s) of the survivin spliced variants has not been 
straightforward, complicated by the low levels of expression of these 
molecules in most cells, and the limited availability of specific reagents that 
discriminate between the different isoforms. For instance, survivin-2B has 
been reported to promote apoptosis, in vitro. However, low levels of survivin-
2B correlate with better survival in acute myeloid leukemia, and its silencing 
in ovarian cancer has been linked to enhanced sensitivity to taxanes in 
resistant tumors. A role of the survivin isoforms in mitosis has been equally 
controversial, as this function has been proposed in some reports, but 
negated in others. 
In this study, we took a multidisciplinary approach combining genome-
wide bioinformatics, analysis of the DNA damage response and evaluation of 
primary patient samples, to investigate a potential role of a spliced survivin 
variant that lacks exon 3 and contains a unique –COOH terminus sequence, 
survivin-∆Ex3 in cancer. We show that survivin-∆Ex3 is differentially 
expressed in cancer, compared to normal tissues, and correlates with 
aggressive disease and markers of unfavorable prognosis.  Unlike other 
survivin variants, survivin-∆Ex3 localizes exclusively to nuclei, and is 
phosphorylated by the DNA damage checkpoint kinase, Chk2, on residues 
Thr79, Ser98 and Thr127 located in its unique –COOH terminus. 
 
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Mutagenesis of Chk2 phosphorylation sites improves survivin-∆Ex3 
stability in tumor cells, inhibits the expression of Ser139 phosphorylated 
H2AX (γH2AX) in response to double strand DNA breaks, and impairs colony 
formation after DNA damage, in vitro. In contrast, Chk2 phosphorylation on 
Thr68 did not affect stabilization of p53, induction of the cyclin-dependent 
kinase inhibitor p21, and homologous recombination-induced repair in 
response to DNA damage.  Active Chk2 was detected at the earliest stages 
of the colorectal adenoma-to-carcinoma transition, persisted in advanced 
tumors, and correlated with increased survivin expression, in vivo. These 
data suggest that Chk2 phosphorylation of survivin-∆Ex3 contributes to a 
DNA damage-sensing checkpoint in tumor cells, which may affect sensitivity 
to anticancer therapies. 
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1. INHIBITOR APOPTOSIS PROTEINS (IAPS) FAMILY 
 
The Inhibitors of Apoptosis Proteins (IAPs) family are a group of anti-
apoptotic proteins that are conserved in several species [Deveraux & Reed, 
1999]. These proteins are characterized by one or more 70–80 amino-acid 
baculoviral IAP repeat (BIR) domains. The BIR domain is the defining 
structural characteristic of IAP molecules. BIRs can be present in a single 
copy or an array of two to three repeats in the N-terminal portion of IAPs, 
which often include additional functional regions such as a RING or CARD 
(caspase-associated recruitment domain) domain near the C-terminus 
(Figure 1). XIAP (X-linked IAP), c-IAP1, and c-IAP2, which are the most 
extensively characterized of the mammalian IAPs, each contain three BIRs 
and a RING domain. BIRs are regions of approximately 70 amino acids that 
contain the variable consensus sequence C(X)2 C(X)6 (X)3 D(X)5 H(X)6 C, 
where X is any amino acid [Deveraux & Reed, 1999], and fold as three-
stranded beta sheets surrounded by four alpha helices [Hinds et al., 1999; 
Sun et al., 1999; Sun et al., 2000; Verdecia et al., 2000]. The BIR helices and 
beta strands pack tightly to form a hydrophobic core, at the center of which 
lies an atom of zinc coordinated by the three cysteines and the histidine. 
BIRs function principally by mediating protein-protein interactions. The 
presence of multiple copies in a molecule can increase the affinity for a given 
protein as well as the range of proteins with which the IAP can interact. 
Interestingly, the binding properties of sequentially corresponding BIRs in 
multi-BIR-containing molecules is conserved, with BIR2 and -3 involved in 
the binding of caspases and apoptosis-regulatory molecules, and BIR1 
	
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interacting with a diverse array of signaling intermediates [Srinivasula & 
Ashwell, 2008]. They were first discovered in baculoviruses, a group of 
viruses specific to insects [Birnbaum et al., 1994] and proteins containing BIR 
domains have been identified in a wide range of eukaryotic species  and 
several mammalian species including mice, rats, chickens, pigs, and humans 
[Deveraux & Reed, 1999].  
The first mammalian IAP homologue to be identified was neuronal 
apoptosis inhibitory protein (NAIP) (Figure 1), which was isolated during a 
positional cloning effort to identify the causative gene for spinal muscular 
atrophy [Roy et al., 1995]. In contrast to the baculoviral IAPs, which possess 
two BIR domains and a carboxy-terminal RING zinc-finger, NAIP encodes 
three BIR domains and contains a very large and unique central carboxy-
terminus containing a nucleotide-binding oligomerization domain (NOD) and 
a C-terminal leucine-rich repeat (LRR) [Koonin & Aravid, 2000] (Figure 1). 
The NOD and LRR domains regulate the NAIP BIR interaction with caspase-
9 in a manner not seen in any other members of the family (Davoodi et al., 
2004). The full length NAIP binds caspase-9 only in the presence of ATP or 
in the absence the LRR domain, indicating that access to BIRs is spatially 
blocked by the C-terminal domains and that ATP-mediated conformational 
changes are required for caspase-9 binding.  
Subsequent to the identification of NAIP, the IAP family expanded with the 
identification of cellular IAP1 (cIAP1, hIAP2), cIAP2 (hIAP1), and X-
chromosome-linked IAP (XIAP), all of which contain three BIR domains and a 
carboxy-terminal RING finger [Rothe et al., 1995; Duckett et al., 1996; Liston 
et al., 1996; Uren et al., 1996] (Figure 1). Finally were identified survivin (with 
	
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a single BIR and the carboxy-terminal coiled-coil domain) [Ambrosini et al., 
1997], Livin or ML-IAP (with a single BIR and the carboxy-terminal RING 
finger) [Lin et al., 2000; Vucic et al., 2000; Kasof & Gomes, 2001], the testis-
specific IAP (Ts-IAP, with a single BIR and the carboxy-terminal RING finger) 
[Lagace et al., 2001; Richter et al., 2001], and the Apollon/BRUCE (with a 
single BIR and the carboxy-terminal ubiquitin-conjugating enzyme) 
[Hauser et al., 1998; Verhagen et al., 2001] (Figure 1). 
 
 
 
 
 
 
 
 
Figure 1. Schematic structure of the domains of the mammalian IAP family. 
The first mammalian IAP homologue, NAIP, encodes three BIR domains and a 
very large and unique carboxy-terminus containing a nucleotide-binding 
oligomerization domain; cIAP1, cIAP2 and XIAP contain three BIR domains 
and a carboxy-terminal RING finger; survivin contains a single BIR and the 
carboxy-terminal coiled-coil domain; Livin and Ts-IAP encode a single BIR and 
carboxy-terminal RING finger; and BRUCE contains a single BIR and an UBC 
motif. 
 
 
The characterization of IAP proteins suggests that they function as 
suppressor of cell death in a variety of tissue culture systems, including 
triggers of both the endogenous and exogenous pathways of apoptosis 
[LaCasse et al, 1998; Deveraux & Reed, 1999; Wright & Duckett, 2005]. It 
NAIP 1403
cIAP1 618
cIAP2 604
XIAP 497
Survivin 142
Livin 298
Ts-IAP 237
BRUCE 4845
BIR              CARD           UBC          Ring
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was subsequently shown that the IAPs could directly inhibit the activity of 
several recombinant caspases in vitro [Deveraux et al, 1997; Roy et al, 1997; 
Maier et al, 2002], and structure-function studies of IAP family proteins have 
demonstrated a requirement for at least one BIR domain for suppression of 
apoptosis, although other domains found within some IAPs may also be 
required under certain circumstances. Several of the mammalian, fly, and 
viral IAPs have a RING domain located near their carboxyl termini (Figure 1). 
The necessity for the RING domain for suppression of apoptosis appears to 
depend on cellular context. In fact, some reports have indicated that the 
baculoviral IAPs require both amino-terminal BIR domains and the carboxy-
terminal RING domain for their anti-apoptotic function in insect cells [Clem & 
Miller, 1994; Harvey et al, 1997]. By contrast, the human proteins cIAP1, 
cIAP2, and XIAP have been reported to retain anti-apoptotic function in the 
absence of their carboxy-terminal RING domains [Deveraux et al, 1997; Roy 
et al, 1997; Takahashi et al, 1998].  
The BIR domains of the IAPs are the most fully characterized functional 
units of the IAPs. Each BIR domain folds into a functionally independent 
structure that chelates a zinc ion and consists of a globular head and an 
unstructured tail derived from the amino-terminal ‘linker’ region located 
upstream of the individual BIR domains. Specific interactions with initiator 
(caspase-9) and effector (caspase-3 and -7) caspases have been mapped to 
individual BIR domains. As a general rule, the IAPs containing multiple BIRs 
employ the third BIR domain to inhibit caspase-9, and the second BIR 
domain functions to inhibit caspase-3 and -7 [Roy et al, 1997; Takahashi et 
al, 1998; Maier et al, 2002]. As regards single BIR-containing proteins, Ts-
	
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IAP inhibits caspase-9 [Richter et al, 2001], while the survivin and livin inhibit 
caspase-3, -7 and -9 [Lin et al, 2000; Vucic et al, 2000; Kasof & Gomes, 
2001; Shin et al, 2001]. 
Among the mammalian IAPs that are known to be involved in apoptosis, 
X-linked IAP (XIAP) has been characterized extensively (Figure 2).  
 
 
 
 
 
 
 
Figure 2. Map of XIAP activities and interactions. 
XIAP contains three BIR domains and a C-terminal RING motif. 
BIR2 binds to and inhibits active caspase-3 and caspase-7, 
whereas BIR3 potently targets active caspase-9. No specific 
function has been identified for the BIR1 domain. SMAC/Diablo 
peptide, released from mitochondria during apoptosis, binds to a 
highly conserved surface groove on the BIR3 domain of XIAP, and 
re-activates the processed initiator and effector caspases. 
 
 
This protein contains three BIR domains and a C-terminal RING motif. The 
second BIR domain (BIR2) specifically binds to and inhibits active caspase-3 
and caspase-7, whereas BIR3 potently targets active caspase-9 [Shi, 2002]. 
No specific function has been identified for the BIR1 domain of XIAP. The 
linker segment that immediately precedes the BIR2 domain of XIAP binds to 
the active site of effector caspase-3 and caspase-7, hence, preventing 
substrate binding and subsequent catalysis. By contrast, the BIR3 domain of 
caspase-3 
and -7
inhibition
caspase-9
inhibition
SMAC/Diablo
binding
Caspase cleavage
Site 
BIR1 BIR2 BIR3 Ring
	

	 
 23 
XIAP employs a different method to inhibit the initiator caspase, caspase-9. 
Caspase-9 becomes catalytically active through a conformational change 
when bound by Apaf-1, and thus appears to be unique among the caspases 
in that there is no absolute requirement for proteolytic activation. In addition 
to its ability to proteolytically process caspase-3, caspase-9 can undergo a 
self-cleavage event in the linker region between the p20 and p10 subunits. 
The XIAP BIR3 domain directly binds caspase-9 via this newly exposed 
amino terminus and the interaction is stabilized through additional contacts 
with the enzyme. Using purified caspase-9 and XIAP BIR3, in the absence of 
Apaf-1 and cytochrome c, it was demonstrated that this interaction prevents 
caspase-9 homodimerization and stabilizes the enzyme in an inactive state 
similar to its monomeric form [Shiozaki et al, 2003]. It has been proposed that 
a similar change in caspase-9 morphology occurs within the apoptosome 
complex as a consequence of XIAP binding. Caspase-9 can also undergo 
further cleavage catalysed by caspase-3. This proteolytic event further 
increases the enzymatic activity of caspase-9, and was proposed to remove 
the peptide sequence that binds XIAP [Srinivasula et al, 2001].  
In the intrinsic cell death pathway, the key event leading to the activation 
of caspases is the release of several pro-apoptotic proteins from the 
intermembrane space of mitochondria into the cytosol [Wang, 2001]. One 
such protein is SMAC/Diablo [Du et al, 2000; Verhagen et al, 2000]. The 
newly synthesized SMAC/Diablo protein contains 239 amino acids. Its N-
terminal 55 residues encode the mitochondrial-targeting sequence and are 
proteolytically removed in the mature SMAC/Diablo protein [Du et al, 2000]. 
This cleavage results in the exposure of four hydrophobic amino acids, Ala-
	
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Val-Pro-Ile, at the N-terminus of mature SMAC/Diablo. This tetrapeptide 
represents the founding member of a family of IAP-binding motifs in 
mammals and fruit flies [Shi, 2002]. Structural analysis reveals that this 
tetrapeptide motif binds to a highly conserved surface groove on the BIR3 
domain of XIAP [Liu et al, 2000; Wu et al, 2000] (Figure 2). The interactions 
between SMAC/Diablo and IAPs requires that the N-terminus of the 
tetrapeptide is exposed, which explains why only the mature form of 
SMAC/Diablo is functional in cells. Before apoptosis, accidental activation of 
either caspase-9 or caspase-3 and caspase-7 might not lead to cell death 
because of the inhibitory effect of IAPs. During apoptosis, SMAC/Diablo is 
released from mitochondria and re-activates the processed initiator and 
effector caspases by relieving IAP-mediated inhibition. 
  
	

	 
 25 
2. SURVIVIN 
 
Survivin is a bifunctional protein that facilitates tumour cell evasion from 
apoptosis and promotes mitotic progression [Altieri & Marchisio, 1999].  
Survivin was discovered in 1997 by hybridisation screening of a human 
genomic  library with the cDNA of the effector cell protease receptor-1 (EPR-
1) [Ambrosini et al, 1997]. Survivin has a particular relationship to EPR-1: in 
fact its sequence is complementary to and in the reverse orientation of EPR-
1.  
 
2.1. Protein Structure of Survivin & Isoforms 
 
The survivin human gene spans 14.7 kb, and is located on the telomeric 
position of chromosome 17 at band q25 [Ambrosini et al, 1998]. It comprises 
three introns and four exons, a TATA-less proximal promoter, and 
approximately 200 nt GC-rich regions upstream of exon 1 [Ambrosini et al, 
1997]. The gene encodes a 16.5 kDa protein of 142 amino acids. The amino-
terminal portion of survivin consists of three α helices (residues 14-21, 31-41, 
68-80) and 3 β-sheets (residues 43-45, 55-58, 61-64), which closely 
resemble the BIR domain that is conserved in the IAP family [Ambrosini et al, 
1997; Chantalat et al, 2000] (Figure 3). Differently from other IAPs, survivin 
contains only one BIR and a carboxy-terminus coiled-coil, but no RING finger 
or other identifiable domain [LaCasse et al, 1998]. 
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Figure 3. Representation of survivin protein structure. 
The amino-terminal portion of survivin consists of three α 
helices (residues 14-21, 31-41, 68-80) and 3 β-sheets 
(residues 43-45, 55-58, 61-64), which closely resemble the BIR 
domain. Differently from other IAPs, survivin contains only one 
BIR and a carboxy-terminus coiled-coil, but no RING finger or 
other identifiable domain. [Adapted from Verdecia et al, 2000] 
 
 
Crystal structure analysis of survivin revealed that it exists as a dimer, with 
the two BIR domains forming a “bow-tie-shape” [Chantalat et al, 2000] 
(Figure 4). The carboxy-terminal helix is not involved in the dimerization of 
survivin but extends outward from the entwined BIR structure [Chantalat et 
al, 2000].  
 
 
 
 
 
 
Figure 4. Representation of the survivin dimer. 
[Adapted from Verdecia et al, 2000] 
BIR
domain
BIR
domain
65Å
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The survivin gene is subjected to alternative splicing (Figure 5). Human 
survivin gene has four dominant (1, 2, 3, and 4) and two hidden (2B and 3B) 
exons. Alternative splicing of its pre-mRNA give rises to four different 
mRNAs, which encode four distinct proteins, survivin, survivin-2B, survivin-
∆Ex3 [Mahotka et al, 1999], and survivin-3B [Badran et al, 2004] (Figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic representation of the alternative splicing 
variants of survivin. 
Human survivin gene has four dominant (1, 2, 3, and 4) and two hidden 
(2B and 3B) exons. Alternative splicing of its pre-mRNA produces 
different mRNAs, which encode five distinct proteins, survivin, survivin-
2B, survivin-∆Ex3, survivin-3B, and survivin 2α. 
 
 
Survivin (142 aa) is derived from exons 1-4; in survivin-2B (165 aa), the 
BIR motif is interrupted by the in-frame insertion of a novel sequence of 23 
aa derived from a part of intron 2 that is retained as cryptic exon (Figure 5); 
survivin
5’- exon 1 exon 2 exon 3 - 3’exon 4
intron
2
survivin-2B
5’- exon 1 exon 2 exon 3 - 3’exon 4
survivin-∆Ex3
5’- exon 1 exon 2 - 3’exon 4
intron
3
survivin-3B
5’- exon 1 exon 2 exon 3 - 3’
survivin-2α
5’- exon 1 exon 2 intron 2 - 3’
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survivin-∆Ex3 (137 aa) is derived from the joining of exons 2 and 4, skipping 
exon 3 (Figure 5).  
Deletion of exon 3 in survivin-∆Ex3 results in a frame shift after residue 
73P with truncation of the BIR domain in addition to a new COOH-terminal 
protein segment, which in turn might affect functional properties such as 
subcellular localization. Infact, the carboxy-terminal end of survivin-∆Ex3  
contains a bipartite nuclear localization signal, not present in survivin, which 
mediates its strong nuclear accumulation [Rodriguez et al, 2002]. Another 
splice variant, survivin-3B comprises 5 exons including novel exon 3B 
derived from a 165-bp long portion of intron 3. Acquisition of a new in-frame 
TGA stop codon within the novel exon 3B results in an open reading frame 
(ORF) of 363 nucleotides, predicting a truncated 120 amino acid protein. 
Expression of survivin-3B was detected in human colon and gastric 
adenocarcinoma cell lines as well as mononuclear cells prepared from 
patients with MDS and AML. It contains a single BIR, which is critical for 
apoptosis inhibition. However, survivin-3B lacks a carboxyl-terminal coiled-
coil domain, suggesting that survivin-3B may not be associated with G2/M 
phase. These data indicate that the function of survivin-3B may be different 
from that of regular survivin. [Badran et al. 2004]. Morever, an additional 
splice variant, survivin 2α, has been identified [Caldas et al, 2005]. 
Structurally, the transcript consists of 2 exons: exon 1 and exon 2, as well as 
a 3' 197 bp region of intron 2 (Figure 5). Acquisition of a new in-frame stop 
codon within intron 2 results in an open reading frame of 225 nucleotides, 
predicting a truncated 74 amino acid protein.  Survivin 2α is expressed at 
high levels in several malignant cell lines and primary tumors. Functional 
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assays show that survivin 2α attenuates the anti-apoptotic activity of survivin. 
[Caldas et al, 2005a].  
Little is known about the differential functions of survivin alternative splice 
forms, which are generally expressed at lower levels than the wild-type 
survivin. However, it has been reported that the expression of survivin-2B is 
predominant in some neuroblastoma with a good prognosis, but it is 
expressed at low levels in most malignant tissues [Islam et al, 2000]. In renal 
cell carcinomas (RCC), while the expression levels of survivin and survivin-
∆Ex3 did not show a decrease in late tumour stages in comparison with the 
early and intermediate tumour stages in 57 clinical RCC samples, survivin-2B 
expression was significantly decreased in late tumour stages [Mahotka et al, 
2002a], indicating a possible unfavourable role of these splicing variant in the 
development of this tumour type. In gastric cancer, the expression of 
survivin-∆Ex3, survivin-2B, and survivin (dominant transcript) was found in 
clinical samples, irrespective of their histological type, grade, or stage [Krieg 
et al, 2002; Meng et al, 2004]. However, survivin-2B expression was 
significantly decreased in later tumour stage in comparison with early stage 
[Krieg et al, 2002; Meng et al, 2004], and inversely correlated with tumour 
differentiation and invasion [Meng et al, 2004]. The expression of survivin 
and survivin-∆Ex3 remained unchanged in different stages of cancer [Krieg 
et al, 2002], and the expression level of survivin-∆Ex3 is inversely correlated 
with apoptotic  index [Meng et al, 2004]. It was also reported that survivin-2B 
expression was dominant in benign brain tumours in comparison with the 
malignant ones [Yamada et al, 2003], and that survivin-∆Ex3 expression was 
prominent in comparison with survivin-2B expression in survivin-expressing 
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acute lymphocytic leukaemia and chronic lymphocytic leukaemia patient 
bone marrow samples [Nakagawa et al, 2004].  
Preliminary data would suggest that heterodimerisation of survivin with 
survivin-∆Ex3 is essential for the inhibition of mitochondrial-dependent 
apoptosis [Caldas et al, 2005b], further suggesting a possible anti-apoptotic 
role for survivin-∆Ex3. In addition, the different subcellular localisation of 
survivin-∆Ex3 (in nucleus) and survivin-2B (in cytoplasm) [Mahotka et al, 
2002b] suggests their potential different functions. These observations 
indicate that survivin-∆Ex3 and survivin-2B may play an opposing role in 
tumour progression and tumorigenesis. Moreover, it has been demonstrated 
in exogenous expression assays that survivin 2α attenuates the anti-
apoptotic activity of survivin [Caldas et al, 2005a]. More recently, it was 
reported that despite their ability to interact with wild-type survivin, alternative 
splice isoforms such as survivin-∆Ex3 and survivin-2B do not play a role in 
mitosis since they do not localize with the chromosomal passenger complex 
in vivo as a consequence of their reduced affinity for the survivin partner 
Borealin [Noton et al, 2006]. Moreover, these splice variants cannot rescue 
cell proliferation inhibited by RNAi-mediated survivin depletion 
[Noton et al, 2006].  
Bladder cancer development and progression are complicated processes. 
Differen studies have shown the importance of the survivin gene in the 
development and progression of bladder tumors [Hou et al, 2006, Wang et al, 
2008]. After siRNA interference inhibited the expressions of survivin, survivin-
∆Ex3, and survivin-2B in bladder cancer, downregulating these 3 genes 
simultaneously, rather than downregulating one, enhanced cell apoptosis and 
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increased sensitivity of tumor cells to chemotherapeutic drugs [Wuttig et al, 
2007]. 
He et al. successfully detected the mRNA expressions of survivin, survivin-
∆Ex3, and survivin-2B in 60 bladder transitional cell carcinoma (BTCC)  
tissue samples and their mRNA expression levels in the experimental group 
were all significantly higher than those in the control group. It appears that 
these two splice variants of survivin played certain roles in BTCC 
development and progression. Further analysis showed that the expression 
levels of survivin mRNA were positively correlated to pathologic grade and 
depth of tumor invasion, suggesting that survivin influenced the progression 
of bladder tumor. In addition, there was a positive correlation trend between 
the expression level of survivin-∆Ex3 and pathologic grade. The expression 
level of survivin-∆Ex3 also increased significantly with a rise in pathologic 
grade , suggesting that survivin-∆Ex3 is similar to survivin in affecting bladder 
tumor progression. Moreover, the expression level of survivin-∆Ex3 
significantly increased in grade III BTCC, indicating that survivin-∆Ex3 not 
only had antiapoptosis activity but also promoted the proliferation of tumor 
vascular endothelial cells [Caldas et al, 2007], which accelerated bladder 
cancer progression. This finding suggested that survivin-∆Ex3 can be used 
as a potential index to evaluate bladder cancer prognosis and also a 
selectively blocked target in the future. 
In a recent study, the expression level of survivin and its splice variant, 
survivin-∆Ex3, in tumoral, non-tumoral and adjacent non-neoplastic tissues 
was analyzed. In previous reports on the expression of the survivin in thyroid 
tumors, it was revealed that the high expression of survivin was correlated 
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with thyroid tumors [Ito et al, 2003; Xiang et al, 2007], but a comprehensive 
data about the expressional level of survivin and its splice variants in tumoral 
and non tumoral thyroid nodules has been very rare until now.  
It has been reported that the survivin and its splice variants are highly 
expressed in several human carcinoma including lung, breast, colon and 
oesophageal compared with normal tissues [Futakuchi et al, 2007;  Zaffaroni 
et al, 2005; Yamada et al, 2003; Atlasi et al, 2009; He et al, 2009; Ryan et al, 
2005; Suga et al, 2005]. Moreover Ito et al. [2003], reported the high 
expression level of survivin in human thyroid tumors using 
immunohistochemistry technique.  
Vandghanooni et al. [2011] showed a significantly high expression level of 
survivin in malignant papillary thyroid carcinoma compared with others. They 
also found a significant increased expression level of survivin-∆Ex3 in 
malignant tumors compared with adjacent non-neoplastic tissues and non-
tumoral ones. In addition, survivin-∆Ex3 was significantly elevated in 
malignant tumor tissues compared with benign tumors.  
Survivin exhibits cell cycle-dependent expression at mitosis. This requires 
canonical CDE/CHR boxes in the proximal survivin promoter [Kobayashi et 
al, 1999; Badie et al, 2000] acting as G1-repressor elements to shut down 
gene transcription in interphase cells [Kobayashi et al, 1999]. Survivin levels 
are regulated by rapid changes in protein stability. Poly-ubiquitination on 
multiple Lys residues and proteasomal-dependent destruction has been 
proposed as a mechanism to maintain low levels of survivin in interphase 
cells [Zhao et al, 2000], thus further enhancing cell cycle periodicity. In addition, 
mitotic phosphorylation of survivin on Thr34 by p34cdc2-cyclin B1 has been 
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associated with increased survivin stability at metaphase [O’Connor et al, 
2002]. It has been suggested that this pathway is dominant in normal cells 
and constitutes the primary function of survivin in adult tissues [Yang et al, 
2004; Altieri, 2006].  
Other non-cell-cycle-dependent mechanisms driving survivin gene 
transcription independent of mitosis have been described, which involve 
tissue patterning circuits (Wnt/β-catenin) [Kim et al, 2003], cytokine activation 
(STAT3) [Gritsko et al, 2006], costimulatory messages (OX-40) [Song et al, 
2005] and pleiotropic signaling mechanisms (AkT, NFkB) [Mitsiades et al, 
2002] that are operative during development and generally up-regulated in 
cancer cells [Vogelstein & Kinzler, 2004] and can explain survivin 
overexpression in the large majority of human tumours. It has been recently 
suggested that these non-cell-cycle-dependent pathways are dominant in 
tumours. This hypothesis also relies on the fact that a transgenic mouse 
model expressing the green fluorescent protein reporter gene under the 
control of the minimal survivin promoter demonstrated that expression of 
survivin in development and tumour formation is largely independent of cell-
cycle-dependent transcription of the survivin gene at mitosis [Xia & Altieri, 
2006]. The fraction of survivin produced through these non-cell-cycle–
dependent mechanisms mediates apoptosis inhibition through intermolecular 
cooperation with cofactors including the hepatitis B virus X interacting protein 
[Marusawa et al, 2003], a target of the oncogenic viral HBX protein, and XIAP 
[Dohi et al, 2004a].  
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2.2. Survivin & Inhibition of Apoptosis 
 
Survivin plays an important role in the suppression of apoptosis by either 
directly or indirectly inhibiting the activity of caspases (Figure 6).  
 
 
 
Figure 6. Function of survivin as inhibitor of apoptosis. 
Upon activation of proapoptotic cell signaling, survivin is released from the mitochondria in 
the cytosol and inhibits active caspase-9. This function requires association with the hepatitis 
B X-interacting protein and/or with X-linked IAP and is inhibited by Smac/Diablo (Adapted 
from Mita et al, Clin Cancer Res, 2008). 
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However, the role of survivin in apoptosis inhibition has been the subject 
of controversy. Initially, survivin and other IAPs were postulated to selectively 
bind to and promote the degradation of active caspase-3, caspase-7, and 
caspase-9 [Altieri, 2003]. In support of this model, it was shown that survivin 
is inhibited by Smac/DIABLO, thus placing survivin in a central position in the 
dynamic balance of proapoptotic and antiapoptotic factors [Dohi et al, 2004a]. 
However, this model was challenged by the observations that survivin lacks 
the structural motifs that mediate binding to caspases that are present in 
other IAPs and that the role of survivin-like orthologues in Caenorhabditis 
elegans and other organisms seemed exclusively involved in cell division but 
not in cytoprotection [LaCasse et al, 1998]. Later experiments indicated that 
survivin inhibits active caspase-9 but not active caspase-3 and caspase-7 
and that the inhibition of caspase-9 requires a cofactor, the hepatitis B X-
interacting protein [Marusawa et al, 2003]. Additionally, it was suggested that 
the antiapoptotic role of survivin could be mediated by its association with X-
linked IAP via their conserved baculovirus–inhibitor of apoptosis domain, thus 
increasing X-linked IAP stability and leading to the synergistic inhibition of 
caspase-9 activation [Dohi et al, 2004b]. Therefore, the ability of survivin to 
inhibit apoptosis seems likely although its mechanism of action may be more 
sophisticated than direct caspase inhibition and could involve cooperation 
with other molecules (such as hepatitis B X-interacting protein and X-linked 
IAP). 
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2.3. Survivin & Cell Division 
 
The role of survivin in cell division is unanimously accepted. During the 
cell cycle, survivin localizes to various components of the mitotic apparatus 
[Vagnarelli & Earnshaw, 2004] (Figure 7). 
The tightly cell-cycle–dependent control of the synthesis and degradation 
of survivin in normal tissues strongly supports its role in mitotic regulation. 
During mitosis, survivin functions in a narrow time window at metaphase and 
anaphase and localizes to two main subcellular pools. One pool of survivin is 
directly associated with polymerized tubulin. This pool involves centrosomes, 
microtubules of the metaphase and anaphase spindle, and the remnants of 
the mitotic apparatus, and suggests a regulation of microtubule dynamics 
[Li et al, 1998; O’Connor et al, 2002; Giodini et al, 2002; Altieri, 2006]. A 
second pool of survivin localizes to the kinetochores of metaphase 
chromosomes. In this pool, survivin is associated with regulators of 
cytokinesis, such as Aurora B kinase, INCENP, and Borealin/Dasra [Bolton et 
al, 2002; Wheatley et al, 2001; Sampath et al, 2004; Gassmann et al, 2004], 
which supports a role for survivin as a subunit of the chromosomal passenger 
complex that is essential for proper chromosome segregation and cytokinesis 
[Lens et al, 2006]. Although the functions of survivin as a regulator of 
microtubule dynamics and chromosomal passenger protein may seem 
incompatible, a recently proposed theory of survivin as a central regulator of 
spindle formation may reconcile the two. According to this model, survivin 
mediates the proper targeting of chromosomal passenger proteins to 
	

	 
 37 
kinetochores and, in addition, stabilizes the microtubules, thus contributing to 
bipolar spindle formation [Altieri, 2006]. 
 
 
 
 
 
Figure 7. Function of survivin in mitosis. 
Survivin is a component of the chromosomal passenger complex that is essential for proper 
chromosome segregation and cytokinesis. Additionally, a distinct pool of survivin is directly 
associated with polymerized tubulin and contributes to the regulation of microtubule 
dynamics. (Adapted from Mita et al, Clin Cancer Res, 2008). 
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2.4. Regulation of Survivin Function 
 
A critical requisite for survivin function was identified in the 
phosphorylation on threonine 34 [O’Connor et al, 2000]. The only kinase 
recognized to phosphorylate survivin is p34cdc2-cyclinB1, a cyclin-dependent 
kinase that is only active during certain points in the cell cycle [O’Connor et 
al, 2000]. The p34cdc2-cyclin B1 was shown, in vivo, to physically associate 
with survivin and to phosphorylate survivin on Thr34 during mitosis. A direct 
link between survivin and p34cdc2-cyclin B1 was independently confirmed 
using array technology in gene-profiling studies of large-cell non-Hodgkin’s 
lymphoma; it was associated with an activated B-cell phenotype and 
unfavourable disease progression [Kuttler et al, 2002]. Mutants of p34cdc2-
cyclin B1 prevent survivin phosphorylation, and the enzyme can be co-
immunoprecipitated with survivin in cells that have been synchronized in 
mitosis. Although other members of the cdc2 family of kinases may also 
associate with survivin [Suzuki et al, 2000], they are active only during certain 
cell cycle transitions, and thus the activity of survivin as an apoptosis-
blocking protein is likely restricted to dividing cells. The p53-dependent 
repression of cdc2 expression has been demonstrated during G2-arrest 
[Passalris et al, 1999], suggesting the hypothesis that p53 loss is associated 
with greater phosphorylation of survivin and thus more complete suppression 
of apoptosis.  
Expression of non-phosphorylatable survivin Thr34→Ala prevented 
phosphorylation of endogenous survivin, resulting in apoptosis of various 
cancer cell types [O’Connor et al, 2000], and suppressed cell growth in vivo 
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[Grossman et al, 2001; Mesri et al, 2001]. Moreover, inhibitors of cyclin-
dependent kinases (cdk) such as flavopiridol or the more p34cdc2-specific 
inhibitor, purvalanol A, were tested in tumour cells arrested at mitosis with 
paclitaxel, which induces hyperphosphorylation of survivin on Thr34 [Zaffaroni 
et al, 2002]. Sequential administration of cdk inhibitors resulted in escape 
from the mitotic block imposed by paclitaxel, marked activation of 
mitochondrial-dependent apoptosis and anticancer activity in vivo [O’Connor 
et al, 2002].  
A physical interaction with the molecular chaperone heat shock protein 90 
(Hsp90), which involves the Hsp90 ATPase domain and the survivin BIR 
domain, was shown to be essential for the stability and function of survivin. In 
fact, targeted antibody-mediated disruption of the survivin-Hsp90 complex in 
cancer cells resulted in proteasomal degradation of survivin, mitochondrial-
dependent apoptosis, and mitotic arrest [Fortugno et al, 2003]. 
 
 
2.5. Survivin Expression in Normal & Tumour Tissues 
 
One of the most significant features of survivin is its differential expression 
in cancer versus normal tissues. Survivin expression in normal tissues is 
developmentally regulated and the protein was found to be absent or low in 
most terminally differentiated tissues [Ambrosini et al, 1997]. However, recent 
studies tend to attribute a role to survivin in regulating the function of normal 
adult cells [Fukuda et al, 2006] including vascular endothelial cells [Mesri et 
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al, 2001], polymorphonuclear cells [Altznauer et al, 2004], T cells [Xing et al, 
2004], erythroid cells [Gurbuxani et al, 2005], and haematopoietic progenitor 
cells [Fukuda & Pelus, 2001]. Moreover, survivin expression was reported in 
adult liver cells [Deguki et al, 2002], gastrointestinal tract mucosa [Chiou et 
al, 2003] and ovarian granulosa cells [Wang et al, 2004]. However, although 
survivin is expressed in normal tissues characterized by self-renewal and 
proliferation, its expression is significantly lower than in transformed cells. In 
fact, several studies have demonstrated strong survivin expression in most 
human solid tumour types and haematologic malignancies [Altieri, 2003]. 
Expression of survivin has also been detected in a variety of benign and 
preneoplastic lesions including polyps of the colon, breast adenomas, 
Bowen’s disease and hypertrophic actinic keratosis [Altieri, 2003], suggesting 
that re-expression of survivin may occur early during malignant 
transformation or following a disturbance in the balance between cell 
proliferation and cell death. The up-regulation of survivin at the transcriptional 
level in human tumours has been confirmed in genomewide searches, which 
indicated survivin as the fourth top ‘transcriptome’ in cancers of various 
histology [Velculescu et al, 1999]. Moreover, global deregulation of the 
survivin gene mediated by oncogenes such as STAT3 [Gritsko et al, 2006], 
E2F [Jiang et al, 2004], and activated H-Ras [Sommer et al, 2003; Fukuda & 
Pelus, 2004], or by loss of tumour suppressors like wild type p53 [Hoffman et 
al, 2002] or the adenomatous polyposis coli protein [Zhang et al, 2001], 
seems to be responsible for the enhanced expression of survivin in tumours.  
Growing evidence suggests that survivin expression in cancer cells is 
associated with clinicopathologic variables of aggressive disease and may 
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represent an important prognostic marker for patient outcome. In fact, several 
studies on different types of solid tumours and haematologic malignancies 
showed that high levels of the protein were predictive of tumour progression 
in terms of either disease-free or overall survival [Altieri, 2003]. In several 
neoplasms the association with tumour progression was corroborated in the 
context of a comprehensive analysis of gene-expression profiling by DNA 
microarray or PCR-based assay. As it is possible to immunohistochemically 
distinguish two intracellular pools of survivin, a nuclear and a cytosolic one, 
the prognostic significance of the protein has been analyzed in some studies 
as a function of its intracellular localization, and inconsistent and sometimes 
contrasting results have been obtained regarding the prognostic value of 
nuclear survivin expression [Fengzhi et al, 2005]. The different prognostic 
value of survivin may reflect differences in methods to detect its expression 
and/or a differential expression of survivin splice variants.  
 
 
2.6. Survivin as a Determinant of Treatment Resistance 
 
Considering that apoptosis is the primary mode of cell death induced by 
several classes of chemical and physical agents commonly used in cancer 
therapy, it has been hypothesized that survivin expression/up-regulation 
could be crucial in determining the chemo- and radio-sensitivity profiles of 
tumour cells. This possibility is supported by several experimental evidences 
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demonstrating that survivin is able to counteract a broad range of different 
apoptotic stimuli.  
Giodini et al [2002] first reported that infection of HeLa cells with an 
adenoviral vector expressing survivin suppressed apoptosis induced by taxol. 
Successively, studies performed on human ovarian carcinoma cell lines and 
clinical specimens clearly indicated that survivin is involved in regulating cell 
sensitivity to taxanes. Specifically, the OAW42 and IGROV-1 human ovarian 
cancer cell lines were transfected with the human survivin cDNA. Stable 
transfection with survivin cDNA was able to protect these cells from the 
cytotoxic effects induced by paclitaxel and taxotere, with IC50 values for the 
survivin-transfectant cell populations 4-6-fold those of the control cells 
[Zaffaroni et al, 2002]. Zhang et al [2005] showed that forced expression of 
wild type survivin in human prostate cancer cell lines increased the 
resistance to taxol in vitro and in vivo. In addition, in the clinical setting, in 
advanced ovarian cancer patients receiving a paclitaxel+platinum-based 
regimen, the overexpression of the anti-apoptotic protein correlated with a 
lower clinical or pathologic complete remission rate (with respect of those 
treated patients where survivin expression was found to be low or absent) 
[Zaffaroni et al, 2002]. 
It has been reported that taxol-induced microtubule stabilization and 
mitotic arrest increase the expression of survivin, which engenders a cell 
survival pathway to counteract taxol-induced apoptosis [O’Connor et al, 
2002]. Interestingly, using a taxol-resistant ovarian cancer cell clone, PTX10, 
with a β-tubulin mutation at the taxol binding site, Zhou et al [2004] found that 
taxol treatment failed to induce mitotic arrest and survivin expression. 
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However, the finding that taxol induced an apoptotic response in these cells 
suggests that mitotic arrest is not strictly required for taxol-induced apoptosis. 
It is also possible that the mitotic survival pathway is not the only one by 
which cancer cells counteract taxol-induced apoptosis. In fact, Ling et al 
(2004) reported that induction of survivin by taxol in MCF-7 cells is an early 
event and is independent of taxol-mediated G2/M arrest, suggesting a role for 
survivin in taxol resistance not only during mitosis but outside of the mitotic 
checkpoint as well. There is evidence that the mTOR pathway, which 
constitutes a sensor network for stress conditions, is involved in resistance to 
paclitaxel by increasing survivin levels [Vaira et al, 2006]. In fact, it has been 
recently reported that IGF-1-mediated mTOR activation in prostate cancer 
cells positively modulated survivin levels by favoring stabilization and 
translation of a survivin mRNA pool, and that mTOR inhibition with 
rapamycin, alone or in combination with paclitaxel, abolished survivin 
increase. Consistent with a critical reduction of the anti- apoptotic threshold 
maintained by survivin, the paclitaxel plus rapamycin combination was more 
effective than either treatment in reducing cell viability of in the presence of 
IGF-1 [Vaira et al, 2006]. 
An increase in survivin expression has also been reported in prostate 
cancer [Nomura et al, 2005] and thyroid cancer [Tirro et al, 2006] cell lines 
permanently resistant to cisplatin as well as in colorectal cancer cells 
resistant to TRAIL [van Geelen et al, 2004]. Zhang et al (2005) showed that 
survivin mediates resistance to anti-androgen therapy with flutamide in 
prostate cancer cells. Specifically, these authors suggested that up-
regulation of survivin via insulin-like growth factor-1/AKT signaling during 
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androgen blockade may be one of the mechanisms by which prostate cancer 
cells develop resistance to anti-androgens. Paik et al. (2004) showed that 
survivin was one of the sixteen genes predictive of recurrence in tamoxifen-
treated breast cancer patients.  
Regarding the role of survivin in determining the response of human 
tumour cells to radiation, Asanuma et al. (2000) first reported that survivin 
acts as a constitutive radio-resistance factor in pancreatic cancer cells. 
Specifically, in a panel of established cell lines they found an inverse 
relationship between survivin mRNA expression and in vitro sensitivity to X-
irradiation. Moreover, they demonstrated that survivin mRNA expression was 
increased by sublethal doses of X-irradiation, which would suggest that the 
protein also acts as an inducible radioresistance factor. Rodel et al (2003) 
also showed an inverse correlation between survivin expression and 
apoptotic response to irradiation in a panel of colorectal carcinoma cell lines. 
More recently, in a translational study of 59 rectal cancer patients treated 
with a combination of radiotherapy and chemotherapy, the same authors 
reported that increased survivin expression was associated with a 
significantly increased risk of local tumour recurrence [Rodel et al, 2005]. It is 
worthy of note that survivin can contribute to radiation resistance also by 
promoting the survival of tumour vascular endothelial cells. In fact, induction 
of vascular endothelial apoptosis was recently shown to be a major 
determinant of overall tumour response to radiotherapy [Garcia-Barros et al, 
2003]. Radiation may induce tumour cells to secrete cytokines such as 
vascular endothelial growth factor, which in turn could inhibit radiation-
induced apoptosis of vascular endothelial cells by up-regulating survivin 
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expression, as already demonstrated for drug-induced apoptosis 
[Tran et al, 2002]. 
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3. SURVIVIN DIRECTED CANCER THERAPY 
 
In recent years considerable efforts have been made to validate survivin 
as a new target in cancer therapy. In this context, a collection of different 
approaches to counteract survivin in tumour cells, including antisense 
oligonucleotides, ribozymes, small interfering RNAs (siRNAs) and dominant-
negative mutants, as well as cyclin-dependent kinase inhibitors, have been 
proposed with the dual aim to inhibit tumour growth potential and to enhance 
tumour cell response to apoptosis-inducing anticancer agents [Kappler et al, 
2004; Grossmann et al, 1999; Andersen & Thor, 2002, Ling & Li, 2004] 
(Figure 8). 
 
 
 
 
 
 
 
 
 
 
Figure 8. Summary of the current strategies for survivin 
targeting in cancer therapy. 
A, Molecular antagonists able to target survivin mRNA and inhibit translation; 
B, Dominant negative mutants able to inhibit survivin dimerization or survivin 
activation; C, Small molecule antagonists able to inhibit survivin phosphorylation 
on Thr34 residue (CDK inhibitors) or to counteract survivin-Hsp90 interaction 
(Hsp90 inhibitors). In B and C, the wild type protein is reported in its dimeric 
arrangement [Muchmore et al, 2000]. 
survivin mRNA
AAAA
A
A
AAA
Antisense
siRNA
Ribozyme
C. Small Molecule Antagonists 
A. Molecular Antagonists 
B. Dominant Negative Mutants 
AAAA
A
A
AAA
Cys84Thr34
Cys84Thr
34
Cys84 Thr34
Ala84 Thr
34
Cys84Thr34
Cys84 Thr34
Cys84Ala34
Cys84 Thr34
PP
p34cdc2
CDK 
inhibitors
Hsp90 
inhibitors
Hsp90Hsp90
Hsp90Hsp90
PP
	

	 
 47 
Results from studies exploiting different strategies to interfere with survivin 
expression and function provided direct and convincing evidence that  
targeting the survivin network inhibits tumor growth potential in vitro and in 
vivo and increases spontaneous and treatment induced apoptosis of cancer 
cells, thus indicating survivin as a promising molecular target for cancer 
therapy. Two strategies, antisense oligonucleotides and small-molecule 
inhibitors, have entered clinical development (Table I) YM155 (Astellas 
Pharma) is a small-molecule survivin suppressant selected via a high-
throughput screening assay with a survivin-promoter luciferase assay. It 
selectively inhibits survivin mRNA transcription and protein expression in 
several tumor cell lines and has shown potent (nmol/L) antiproliferative 
activity in a broad spectrum of preclinical models, including prostate, breast, 
ovarian, and non–small cell lung carcinomas and melanoma as well as non–
Hodgkin’s lymphoma and leukemia. Tumor regressions, including complete 
responses, have been observed in xenograft models of non–Hodgkin’s 
lymphoma and prostate carcinoma. 
In a phase I study, 41 patients were treated with a 168-hour continuous 
infusion of YM155 and the activity has been reported with three partial 
responses in non–Hodgkin’s lymphoma, two prostate-specific antigen 
responses in hormone-refractory prostate cancer patients, and one minor 
response in non–small cell lung cancer [Mita et al, 2006].   
The favorable safety profile of YM155 at the recommended dose as well 
as its provocative antitumor efficacy prompted the phase II evaluation of this 
compound in melanoma, prostate carcinoma, and non–Hodgkin’s lymphoma. 
One of these phase II studies reported two prostate-specific antigen 
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responses in 32 patients with hormone-refractory prostate cancer as well as 
an acceptable toxicity profile for YM155 [Karavasilis et al, 2007]. In the 
melanoma study, 1 partial response and 1 minor response were observed in 
the 34 patients, with 2 additional patients experiencing stable disease. The 
non–Hodgkin’s lymphoma study is ongoing, and several combination trials of 
YM155 with cytotoxics as well as with targeted therapies are either planned 
or under way.  
LY2181308 (ISIS 23722; Eli Lilly and Co. and ISIS Pharmaceuticals Inc.), 
a secondgeneration antisense oligonucleotide targeting survivin, is also being 
evaluated in phase I trials. 
Because survivin inhibitors have shown only modest antitumor activity in 
clinical trials, these agents may be best used in combination with 
conventional chemotherapy. Due to the complexity of the proapoptotic and 
antiapoptotic pathways, with multiple players involved, redundant signaling 
networks, and multifaceted interactions between the involved elements, 
blocking only one antiapoptotic factor may not result in robust antitumor 
activity. Therefore, the rather disappointing results of survivin inhibitors 
administered as a single agent in unselected populations in phase II studies 
are not surprising. A molecularbased enrichment of the treated populations 
with subjects more likely to respond to survivin inhibition could overcome, at 
least in part, these caveats. It was suggested that, in diffuse large-cell 
lymphoma, survivin may be the primary mechanism for apoptosis abrogation 
in a significant subset of patients, with another subset being dependent on 
bcl-2 overexpression and a smaller distinct population possibly relying on 
both [Tracey et al, 2005]. Alternatively, the combination of survivin with other 
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proapoptotic factors seems to be an attractive strategy with potentially broad 
clinical applications. There are multiple lines of evidence indicating that 
survivin inhibition potentializes the antitumor activity of several cytotoxics and 
targeted therapies, including topoisomerase inhibitors [Sato et al, 2007], 
alkylating agents [Li et al, 2006], tumor necrosis factora-related apoptosis-
inducing ligand [Wagner et al, 2007], and UCN-01 [Vogel et al, 2007]. 
Overall,survivin inhibitors may represent a novel type of targeted drugs as 
much as they specifically interfere with defined molecular pathways of tumor 
cell maintenance and at the same time are applicable to different tumor types 
independent of their genetic makeup. 
 
Table I. Survivin inhibitors currently in pahse I/II clinical trials. 
 
Therapeutic Approach Compound 
 
Development Phase 
 
Antisense Oligonucleotides 
 
LY2181308 
((ISIS Pharmaceuticals) 
 
EZN3042                   
(Enzon Pharmaceuticals) 
 
Phase I/II 
 
 
                Phase I 
 
 
 
Small antisense molecule  
 
 
 
 
Antagonists of the  
survivin-Hsp90 complex  
 
 
 
YM155 
 (Astellas Pharma Inc)  
 
 
 
Shepherdin 
 
 
Phase I/II 
 
 
 
 
 
NCI-RAID 
   
   
Immunotherapy Autologous CTL Phase I/II 
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4. DNA DAMAGE 
 
A wide diversity of lesions (Figure 9) caused by environmental agents 
such as ultraviolet (UV) radiation in sunlight, ionizing radiation, and numerous 
genotoxic chemicals can arise in the DNA. In addition, the genome is also 
attached by internal products of normal cellular metabolism, such as reactive 
oxygen species (ROS; i.e., superoxide anions, hydroxyl radicals, and 
hydrogen peroxide) derived from oxidative respiration and products of lipid 
peroxidation. These agents can cause a variety of damages in the DNA. 
Cellular response to DNA-damage, during any phase of the cell cycle, is a 
very complex process  and  has the same pattern. After the detection of DNA 
damage by a multitude of proteins that sense the damage, signal transducer 
proteins transduce the signal to effector proteins into cells and execute 
cellular responses (Figure 9). This network of events includes a protein 
kinase cascade that connects the detection of DNA damage to the activation 
of transcription factors, which in turn regulate the expression of genes 
implicated in specific cellular pathways, including DNA repair mechanisms, 
cell-cycle checkpoints, cellular senescence and apoptosis [Zhou & Elledge, 
2000; Sancar et al, 2004]. In response to the different types of DNA damage, 
the cell cycle checkpoints are activated to delay or arrest cell cycle 
progression, presumably in order to allow time to repair damaged DNA 
[Nyberg et al, 2002]. The blockage of DNA replication leads to collapse of 
replication forks and DNA double-strand breaks (DSBs) formation, which are 
thought to be crucial downstream apoptosis triggering lesions [Roos & Kaina, 
2006]. DSBs are recognised by proteins that exert both kinase and repair 
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activity. The most important players in the early response to DNA damage 
consists of two kinases,  members of the phosphatidylinositol-3-kinase-
related family [Durocher & Jackson, 2001; Ismail et al, 2005]: ATM ( Ataxia 
Telangiectasia Mutated ) and ATR (Ataxia Telangiectasia and Rad3 related). 
Ataxia telangiectasia is an autosomal recessive disorder caused by mutated 
ATM, characterized by immunodeficiency, neurological disorders, and high 
cancer susceptibility. ATR was identified later on basis of sequence and 
functional homology to ATM.  These kinases phosphorylate p53 at serine 15 
in response to DNA damage, resulting in the stabilization of the protein and 
subsequently amplifying the downstream p53 cascade and obtaining p21 
blocking the cell cycle [Siliciano et al, 1997]. The ATM and ATR proteins 
belong to the phosphatidylinositol 3-kinase like (PIKK) family of 
serine/threonine protein kinases. This family also includes DNA protein 
kinase (DNA-PK). DNA-PK has an important role in G1/S checkpoint and 
seems to be a DNA double strand break repair enzyme [Durocher & Jackson, 
2001].  
Recent results suggest that the Rad50/Mre11/Nijmegen Breakage 
Syndrome 1 (NBS1) complex and Rad17 protein function as the DSBs 
sensor for ATM [Williams, 2007]. Whereas ATM is activated by ionizing 
radiation-induced DSBs, ATR is activated in response to UV light and 
presumably all chemical agents that give rise to stalled DNA replication forks 
[Dart et al, 2004]. Other candidate DNA damage sensors are three proteins 
Rad9, Hus1, and Rad1 that form a ring structure (the so called “9–1–1” 
complex) that can encircle the damaged DNA and is expected to form a 
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scaffold for downstream checkpoint and repair proteins [Houtgraaf et al, 
2006]. 
 
 
Figure 9. Representation of the DNA-damage-induced 
checkpoint response. 
After the detection of a given damage by sensor proteins, this signal is 
transduced to the effector proteins via the transducer proteins. Depending 
on the phase of the cell cycle in which the cell is, this can lead to activation 
of p53 and inactivation of CDC25, which eventually leads to cell cycle arrest. 
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Upon activation, ATM phosphorylates various downstream substrates 
such as p53, Nbs1, MDC1, 53BP1, Rad9, Chk1 and Chk2, H2AX and 
BRCA1 [Lavin et al, 2005; Roos & Kaina, 2006]. ATM, and presumably also 
ATR, exerts three crucial functions: regulation and stimulation of DSB repair, 
signaling cell-cycle checkpoints and signaling apoptosis via p53 [Lavin et al, 
2005]. Once phosphorylated, p53 becomes stabilised and blocks proliferation 
by up-regulation of p21waf1, which triggers G1/S arrest. It has been suggested 
that at low levels of DSBs only a minor fraction of p53 is activated, driving the 
transcription of the p21 gene and causing cell-cycle arrest. By contrast, with 
high levels of DSBs, p53 becomes metabolically stable and transcriptionally 
activated, and accumulates above a particular threshold, inducing the 
transcriptional activation of pro-apoptotic genes such as Bax (Bcl-2-
associated X protein), PUMA (p53 up-regulated modulator of apoptosis) and 
FAS receptor [Roos & Kaina, 2006]. p53 activation results from post-
translational modifications (i.e., phosphorylations, acetylations or covalent 
attachments of small ubiquitin-like proteins), whereas p53 instability is due to 
its ubiquitination and proteosomal degradation. Both these processes are 
transiently suppressed after DNA damage [Bernstein et al, 2002]. 
Most human tumours lose the expression of a functional p53. However, it 
has been demonstrated that crucial DNA damage can activate a p53-
independent apoptosis via backup systems [Roos & Kaina, 2006]. There are 
several strategies that cells seem to employ to trigger p53-independent DNA 
damage-induced apoptosis. The first one involves the p53 homologs p63 and 
p73 [Roos & Kaina, 2006]. It has been proposed that, upon DNA damage, 
ATM and ATR activate Chk1 and Chk2, which are like ATM and ATR, 
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serine/threonine protein kinases and phosphorylate targets that eventually 
result in the cell cycle arrest.  
The Double Strands Breaks (DSBs) signal sensed by ATM is transduced 
by Chk2, and the UV damage signal sensed by ATR is transduced by Chk1, 
although there is some overlap and redundancy between the functions of 
these two proteins. Chk1 and Chk2 transfer the signal of DNA damage to the 
phosphotyrosine phosphatases and cell division cycle proteins Cdc25A, 
Cdc25B, and Cdc25C. Phosphorylation of Cdc25A–C by Chk1 or Chk2 
inactivates Cdc25A–C, whereas unphosphorylated Cdc25A–C promotes the 
G1/S and G2/M transition by dephosphorylating the cyclin dependent kinases 
(CDKs) directly involved in cell cycle transition. 
The exact pathway of cell cycle arrest depends on the kind of damage. 
DNA DSBs lead to phosphorylation of ATM that subsequently phosphorylates 
Chk2. Single-strand gaps result in the activation of Rad17 or the 9–1–1 
complex, and ATR, which leads to phosphorylation of Chk1. Subsequent 
phosphorylation of Cdc25A by Chk1 or Chk2 causes inactivation of this 
protein by nuclear exclusion and ubiquitin-mediated proteolytic degradation, 
leading to G1 arrest. ATM and ATR also phosphorylate p53, which leads to 
stabilization and accumulation of the p53protein and promotes its 
transcription factor activity. Two pathways mediate, instead, the intra-S-
phase checkpoint. Firstly, the ATM/ATR–Chk2/Chk1– Cdc25A–CDK2 
pathway is more or less similar to the G1/S checkpoint. In the S phase, this 
pathway delays replication (by blocking the loading of Cdc45 onto chromatin 
that in turn attracts DNA polymerase-a into prereplication complexes) and, as 
a consequence, extends the DNA replication time, allowing DNA repair to 
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take place. The second pathway involves Nbs1 which is phosphorylated by 
ATM together with Chk2, leading to a cascade involving also Mre11- and 
Rad50-like initial DSBs recognition, which plays a role not only in cell cycle 
arrest but also in activating the repair processes. When cells encounter DNA 
damage in G2, the G2/M checkpoint stops the cell cycle in order to prevent 
the cell from entering mitosis. As in the G1/S checkpoint, the kind of DNA 
damage determines the pathway that will be activated: ATM–Chk2–Cdc25 for 
DSBs and ATR–Chk1– Cdc25 for DNA lesions such as those created by UV 
light. Besides downregulating Cdc25A, both Chk1 and Chk2 upregulate 
WEE1 by phosphorylation, which together control Cdc2/CyclinB activity. This 
latter complex promotes G2/M transition under normal circumstances, and 
inactivation blocks the cell cycle when damage occurs in G2. 
Activation of Chk1 and Chk2 by ATM and ATR in turn activate E2F1.  This 
in turn stimulates transcription of the p73 gene, giving rise to an increased 
level of p73 protein [Urist et al, 2004]. Whereas p53 requires p63 and p73 for 
triggering apoptosis, p73 has a pro-apoptotic activity even in the absence of 
p53 [Flores et al, 2002; Roos & Kaina, 2006]. p73-induced apoptosis was 
shown to be mediated by transcriptional up-regulation of PUMA, NOXA and 
Bax [Melino et al, 2004; Flinterman et al, 2005].  
Another factor implicated in p53-independent apoptosis is NF-kB (nuclear 
factor-kB), which is generally anti-apoptotic as it transcribes anti-apoptotic 
genes. However, under some circumstances (i.e., topoisomerase inhibitor 
treatment [Piret et al, 1999], NF-kB exhibits pro-damage-signaled apoptosis, 
by inducing the transcription of a growing number of genes related to 
apoptosis, including Fas ligand [Schmitt et al, 2007]. In addition, upon DNA 
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damage RNA synthesis is inhibited, leading to a decline in the level of critical 
gene products such as MKP1 (mitogen-activated protein kinase 
phosphatase) and causing sustained activation of JNK (Jun kinase) and AP-
1, which stimulates death-receptor activation [Roos & Kaina, 2006].  
  
	

	 
 57 
5. DNA REPAIR PATHWAYS 
 
The DNA damage has not only to be prevented, but also to be repaired 
when occurred. As there are many different lesions possible, different types 
of repair pathways have evolved. Important pathways in mammalian cells 
include base excision repair (BER), nucleotide excision repair (NER), 
mismatch repair (MMR), and DSBs repair (Figure 10). 
 
 
Figure 10. Summary of the most common types of DNA lesions that can be caused by 
exogenous or endogenous damaging agents. 
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5.1. DNA base excision repair 
 
The DNA base excision repair (BER) pathway plays a critical role in 
maintaining genetic stability and is is the main guardian against damage due 
to cellular metabolism. BER is responsible for correcting base lesions arising 
from damage due to oxidation, alkylation, deamination and depurination / 
depyrimidination [Xu et al, 2008; Robertson et al, 2009].  
Base damages are generated by ROS, ionizing radiation, and indirectly 
also by UV radiation (via generation of ROS) or can be the result of various 
chemicals like chemotherapeutic drugs (e.g., adriamycin, mitomycin C, and 
psoralen). BER encompasses two general subcategories; short-patch BER 
involves repair of a single nucleotide while long-patch BER produces a repair 
tract of at least two nucleotides. There are four general steps to BER, first a 
glycosylase (depending on the damage) recognizes and catalyzes the 
removal of the damaged base(s). Next a nuclease (APE1 endonuclease) 
causes strand incision. This results in an abasic site, from which both ends 
are trimmed by poly(ADP-ribose) polymerase and polynucleotide kinase to 
facilitate repair synthesis. Finally a ligase seals the broken DNA strand 
(Figure 11). Genetic mutations in BER components have been linked to 
familial colorectal cancer  [Al-Tassan et al, 2002; Jones et al, 2002; Sampson 
et al, 2003; Sieber et al, 2003; Croitoru et al, 2004; Isidro et al, 2004; Venesio 
et al, 2004; Wang et al, 2004; Eliason et al, 2005]. 
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Figure 11. Simplified schematic of DNA base excision repair. 
The base excision repair (BER) pathway plays a critical role in 
maintaining genetic stability and is responsible for correcting base lesions 
arising due to oxidation, alkylation, deamination and depurination / 
depyrimidination. There are four general steps to BER, first a glycosylase 
recognizes and catalyzes the removal of the damaged bases. Next a 
nuclease causes strand incision, followed by gap-filling by a polymerase. 
Finally a ligase seals the broken DNA strand. Replacement of a single 
nucleotide is termed short patch BER while replacement of 2-6 
nucleotides is termed long patch BER. (Adapted from Robertson et al.; 
Cellular and Molecular Life Sciences, 2009.) 
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5.2. Nucleotide excision repair 
 
NER is the most important repair system to remove damage that distorts 
the normal architecture of the DNA helix and bulky DNA lesions that can be 
caused by UV radiation (thymidine dimers), chemicals, or ROS. Disruption of 
the DNA helix interferes with base pairing and hinders transcription and 
normal replication. The repair of damaged DNA involves at least 30 
polypeptides within two different sub-pathways of NER known as 
transcription-coupled repair (TCR-NER) and global genome repair (GGR-
NER) [Reardon & Sancar, 2005]. Repair is much more efficient in actively 
transcribed genes than in the overall genome, and the two pathways differ 
only in the initial DNA damage recognition step. NER includes a lot of 
different proteins but the most important of them are encoded by seven 
xeroderma pigmentosum (XP) complementation groups, XPA to XPG 
genes. 
 
 
5.3. DNA mismatch repair 
 
DNA mismatch repair (MMR) is responsible for recognizing and repairing 
the erroneous insertion, deletion and mis-incorporation of bases that arise as 
a result of replication errors that escape the proofreading function of DNA 
polymerases [Harfe & Jinks-Robertson, 2000; Hsieh & Yamane, 2008]. In 
eukaryotes, MMR begins with the recognition of the mismatch by the MutS 
complex. MutS then works in concert with the MutL complex to facilitate 
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endonucleolytic cleavage by a third MMR protein, PMS2. Single strand 
exonucleases resect the DNA allowing for DNA POLD and Ligase I to repair 
the resulting DNA gap [Hsieh & Yamane, 2008]. Consequently, loss of 
functional MMR leads to microsatellite instability (MSI) and a mutator 
phenotype [Wu et al, 2000; Umar et al, 2004]. 
 
 
5.4. DNA double strand break repair 
 
The described repair systems are efficient only with damaging agents that 
cause single strand lesions but the most dangerous and critical DNA 
damages that occurs on DNA are the double strand breaks (DSBs) . DSBs 
are a very genotoxic type of DNA damage which are primarily repaired by the 
Homologous Recombination (HR) or Non Homologous End Joining (NHEJ) 
pathways in mammalian cells (Figure 12 and 13) [Rothkamm et al, 2003; 
Helleday et al, 2007]. Because both strands of the DNA double helix are 
broken, chromosomal fragmentation, translocation, and deletions can easily 
occur and rapid repair is crucial. DNA DSBs can be caused by ionizing 
radiation, ROS, and chemotherapeutic drugs and can arise during replication 
of a single-strand break. The two main differences between these pathways 
are the requirement for extensive DNA homology on the sister chromatid in 
HR and the accuracy of repair.  
 Figure 12
Under normal conditions, a DNA double strand break (DSB) is sensed by the MRE11
RAD50–NBS1 (MRN) complex. 
PKCS kinases and phosphorylation of the histone variant H2AX (termed 
site of the break. Subsequently, a number of DNA damage sensing proteins (such as MDC1 
and 53BP1) and DNA DSB
nonhomologous end joining (NHEJ) are recruited within the first 1
to repair the DNA DSB. The NHEJ repair pathway can be used within any phase of the cell
cycle and can be error-
of the cell cycle when a homologous sister chromosome or chromatid is available for
base-pairing to effect error
Cancer Reviews, 2008.)
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Figure 13. Simplified schematic of DNA double strand break repair in 
mammalian cells. 
A. Homologous recombination (HR) uses a homologous DNA fragment as a template for 
accurate repair. Free DNA ends at the site of a DSB are first processed followed by 
association of Rad51, Rad52 and RPA with the single-stranded overhangs. This 
nucleoprotein filament searches for homologous DNA and subsequently, a joint molecule is 
formed allowing for template guided DNA synthesis.  
B. Nonhomologous end-joining (NHEJ) does not require the presence of a homologous 
template, but mediates repair by directly rejoining DNA strands. It involves recognition of the 
DSB, processing of non-complementary or damaged DNA ends and the subsequent ligation 
of the DNA termini. Processing of DNA ends can lead to loss or gain of nucleotides, 
rendering NHEJ less accurate than HR. (Adapted from Weterings et al.; DNA Repair, 2004.) 
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DSBs are initially sensed by the MRE11–RAD50–NBS1 (MRN) complex. 
This leads to activation and recruitment of the ataxia telangiectasia mutated 
(ATM) and DNA-dependent protein kinase (DNA-PK) catalytic subunit (DNA-
PKCS) kinases and phosphorylation of the histone variant H2AX (termed 
γH2AX) around the site of the break. Subsequently, a number of DNA 
damage sensing proteins, such as mediator of DNA damage checkpoint 1 
(MDC1) and p53-binding protein 1 (53BP1), and DNA DSB repair proteins 
involved in HR and NHEJ are recruited within the first 1–6 h of damage 
recognition to repair the DNA DSB. HR is a template-guided, error-free repair 
pathway, predominantly operating in the S and G2 phases of the cell cycle as 
it requires a repair template from a sister chromatid or chromosome 
[Rodrigue et al, 2006; Helleday et al, 2007; Ip et al, 2008]. Free DNA ends 
formed at the site of a DSB are first processed to produce single stranded 
DNA (ssDNA) with a 3’-hydroxyl overhang involving the action of the MRN 
complex along with the CtIP, Exo1, BLM and BRCA1 proteins [Ira et al, 2003; 
Lengsfeld et al, 2007; Mimitou et al, 2008; Yun & Hiom, 2009]. Replication 
protein A (RPA) binds and stabilizes the resulting ssDNA [Sung & Klein, 
2006]. RAD51 displaces RPA to form the nucleoprotein filament with the 
assistance of BRCA2 [Sharan et al, 1997; Wong et al, 1997; Pellegrini et al, 
2002]. This nucleoprotein filament subsequently searches for homologous 
DNA and when found facilitates the formation of a D-loop intermediate in 
which the 3’-end initiates DNA synthesis using the duplex DNA as a template 
[Weterings & van Gent, 2004]. 
The joint DNA molecule (termed a Holliday junction) can be resolved by 
the Holiday junction resolvase, GEN1 [Ip et al, 2008] or the BLM-
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topoisomerase IIIα [Wu & Hickson, 2003] or Mus81-Eme1 complexes [Chen 
et al, 2001; Constantinou et al, 2002]. 
In contrast, NHEJ is predominant in G1, but can act throughout the cell 
cycle as it does not require a homologous template for repair. The two ends 
of the broken double helix are directly ligated together by the DNA 
ligaseIV/Xrcc4 complex. It involves recognition of the DSB, processing of 
noncomplementary or damaged DNA ends and the subsequent ligation of 
DNA termini. Processing of DNA ends can lead to loss or gain of nucleotides, 
rendering NHEJ less accurate than HR [Weterings & van Gent, 2004; 
Helleday et al, 2007]. Other proteins involved in this pathway are the Ku70/80 
heterodimer, DNA-PKCS, and the Rad50/Mre11/NBS1 complex.  
Although both DSB repair pathways are operational in mammals, their 
relative contribution differs depending on the stage of the cell cycle or the cell 
type. For HR to occur, there is a need for a sister chromatid, which is not 
produced until the S phase. For this reason, HR can only take place in 
dividing cells that are in the S or G2 phase. Cells in G0 and G1 or terminally 
differentiated cells mainly rely on NHEJ. A number of the previously 
mentioned DNA DSB repair proteins (for instance, Rad51, Rad54, and the 
MRN complex) and γ-H2AX relocate into nuclear foci after induction of DNA 
damage. These foci are rapidly formed. But what is their function? There are 
different hypotheses about that. One of these is that the efficiency of repair 
and signaling may be enhanced by the concentration of factors near the 
lesion that would generate amplification of signals [Celeste et al, 2003]. 
Histone H2AX may function to concentrate proteins near DNA lesions. A 
second hypothesis considers that phosphorylated residues on H2AX may 
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serve as docking sites for the assembly of proteins in chromatin regions 
distal to the breaks. Therefore, γ-H2AX could be involved in the retention of 
repair/signal factors in the vicinity of the lesion [Bassing et al, 2002]. 
The retention and subsequent increase in the local concentration of 
factors may be mediated, in particular, via weak interactions between the 
high-phosphorylated H2AX tail, and specific domains of repair/signaling 
proteins, while the changes in chromatin structure can promote 
intermolecular auto-phosphorylation of ATM even at a distance [Bakkenist & 
Kastan, 2003]. It is still object of debate whether ATM directly senses these 
DSB-induced chromatin alterations or requires specific damage alerting 
‘‘sensors’’. In any case, it is ascertained that H2AX phosphorylation 
determines both chromatin condensation and amassing of repair factors at 
the site of damage. This focal assembly of repair factors complex and 
associated changes in chromatin folding facilitates the juxtaposition of broken 
ends [Ward & Chen, 2001]. At this point, the DNA repair may take place. 
However, this repair is not an easy issue. 
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6. CHECKPOINT KINASE 2 
 
Checkpoint kinase 2 (Chk2) is a multifunctional enzyme whose functions 
are central to the induction of cell cycle arrest and apoptosis by DNA damage 
[Ahn et al, 2004]. Insight into Chk2 has derived from multiple approaches. 
Biochemical studies have addressed Chk2 structure, domain organization 
and regulation by phosphorylation. Extensive work has been done to identify 
factors that recognize and respond to DNA damage in order to activate Chk2. 
In turn a number of substrates and targets of Chk2 have been identified that 
play roles in the checkpoint response. The roles and regulation of Chk2 have 
been elucidated by studies in model genetic systems extending from worms 
and flies to mice and humans. The relationship of Chk2 to human cancer 
studies is developing rapidly with increasing evidence that Chk2 plays a role 
in tumor suppression.  
 
 
6.1. Domains of Chk2 
 
The Chk2 protein consists of three distinct functional domains; an SQ/TQ 
cluster domain (SCD, residues19–69), a forkhead associated domain (FHA, 
residues112–175), and a Ser/Thr kinase domain (residues 220–486) (Figure 
14a). The SCD contains five SQ and two TQ motifs, which satisfy the primary 
substrate motif for ataxia-telangectasia mutated (ATM) kinase [Kim et al, 
1999]. Especially residues 67–70, STQE, are closely related to the refined 
substrate motif (LSQE) of ATM kinase, determined by oriented peptide library 
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search [O’Neill et al, 2000], and T68 was identified to be a key 
phosphorylation site [Bartek et al, 2001; Kastan & Bartek, 2004]. The FHA 
domain is an 80–100 amino acid phosphopeptide binding domain, conserved 
from yeast to human [Li et al, 2000].  
 
 
 
Figure 14. Structure of the human CHK2 gene and CHK2 protein. 
a) The CHK2 gene localizes to chromosome 22q12.1, which spans approximately 50 
kilobases (kb), and consists of 14 exons (black boxes). Numbers below the bars indicate the 
base-pair (bp) range of each exon. Highly homologous fragments of the gene that include 
exons 11 to 14 are found on chromosomes 2, 7, 10, 13, 15, 16, X and Y. 
b) The SQ/TQ-rich, forkhead-associated (FHA) and kinase domains are shown in maroon, 
blue and brown, respectively. Pinheads indicate putative ATM/ATR phosphorylation sites in 
the SQ/TQ-rich region. In vivo phosphorylations of CHK2 on threonine 68 (by ATM/ATR) and 
threonines 383 and 387 in the activation loop (autocatalytic) are indicated. (Adapted from 
Bartek et al.; Nature Reviews Molecular Cell Biology,2001) 
 
 
The domain consists of 11 beta sheets forming a structural core and 
connecting loops conferring diversity in phosphopeptide recognition as 
resolved by structural analyses of several FHA domains with and without 
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phosphopeptides by X-ray crystallography [Durocher et al, 1999; Durocher et 
al, 2000; Li et al, 2002; Stavridi et al, 2002] and nuclear magnetic resonance 
(NMR) spectroscopy [Liao et al, 1999; Liao et al, 2000; Wang et al, 2000; 
Byeon et al, 2001; Yuan et al, 2001]. FHA domains are found in proteins 
involved not only in DNA damage checkpoint pathways, but also kinesin 
family members, transcription factors, Ki-67, and nuclear inhibitors of protein 
phosphatase 1 [Durocher & Jackson, 2002]. The FHA domain functions in 
trans to modulate protein–protein interactions but also in cis to affect other 
functional domains within the protein itself. The kinase domain shares 
homology to other Ser/Thr or Tyr kinases with a Gly-rich region at the vicinity 
of Lys residues in the N-terminal part and Asp as a catalytic residue at the 
active site. 
 
 
6.2. Chk2 & Cancer 
 
Chk2 has established its position as a bona-fide tumor suppressor 
and the list of Chk2 mutations in cancer cells is continuously expanding 
[Bartek & Lukas, 2003]. The first indication of a tumor suppressor function for 
Chk2 came from the finding that a sub-population of families with the Li-
Fraumeni syndrome (LFS), a familial cancer predisposition syndrome usually 
associated with germline TP53 mutation [Evans & Lozano, 1997], contain 
wild type p53 but mutant Chk2 suggesting that germline mutations in the 
CHEK2 gene phenocopy TP53 inactivation [Bell et al, 1999]. The CHEK2 
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allele containing the mutation 1100delC encodes a C-terminally truncated 
protein within the kinase domain and confers increased breast cancer risk 
independent of mutation in the breast cancer susceptibility associated 
(BRCA) loci [Vahteristo et al, 2002; Meijers-Heijboer et al, 2002; Meijers-
Heijboer et al, 2003]. Screening of cancer cell lines has revealed missense 
mutations in all three functional domains in a variety of tumor types [Sodha et 
al, 2002; Schutte et al, 2003; Dong et al, 2003]. The functional impact of 
CHEK2 mutation generally reflects its location. Thus, kinase domain mutants 
lead to faulty kinase activation after ionizing radiation [Wu et al, 2001], while 
FHA domain lesions may accelerate Chk2 degradation [Lee et al, 2001; 
Matsuoka et al, 2001], or may induce structural changes conferring defects in 
protein–protein interaction [Li et al, 2002; Falck et al, 2001a, Falck et al, 
2001b]. It will be of interest to determine at what stage of tumor development 
CHEK2 mutations arise and the precise Chk2 functions that are selected 
against. 
 
 
6.3. Regulation & Activation of Chk2 
 
Chk2 kinase activity is increased following DNA damage induced by 
ionizing radiation, chemotherapeutic agents, or other compounds that harm 
DNA directly or indirectly. Recently, senescence triggered by telomere 
erosion has been implicated as an activating signal for Chk2 [d’Adda di 
Fagagna et al, 2003; Oh et al, 2003]. Signals from damaged DNA are 
transmitted to the ATM kinase, which has a number of substrates involved in 
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the checkpoint cascade [Banin et al, 1998; Canman et al, 1998; Shiloh, 
2003]. Multiple lines of evidence establish a strong link between ATM and 
Chk2. First, Chk2 fails to be activated in A–T cells and restoration of a Chk2-
dependent S-phase checkpoint was observed upon ectopic expression of 
ATM in A–T cells [Matsuoka et al, 1998; Brown et al, 1999; Chaturvedi et al, 
1999]. Second, ATM directly phosphorylates Chk2 at Thr68, a consensus site 
in the SCD domain in vitro [Ahn et al, 2000; Melchionna et al, 2000] and 
alanine mutation of this residue prevents activation of Chk2 by gamma 
irradiation in vivo [ Ahn et al, 2000; Matsuoka et al, 2000; Melchionna et al, 
2000]. The Ataxia-Telangectasia-and-Rad3-related (ATR) kinase may 
similarly phosphorylate Chk2 after high levels of DNA damage or other 
stressors such as ultraviolet radiation (UV) or treatment with the 
ribonucleotide reductase inhibitor Hydroxyurea (HU) [Matsuoka et al, 2000]. 
Chk2 exists as a monomer in unperturbed cells. Following DNA damage, 
Chk2 undergoes dimerization in which a region spanning phosphorylated 
Thr68 in one Chk2 molecule binds to the FHA domain of second molecule 
[Ahn et al, 2002; Xu et al, 2002; Ahn & Prives, 2002]. Dimerization is likely 
followed by multiple intermolecular phosphorylation events including Thr383 
and Thr387 within the auto-inhibitory loop resulting in kinase activation 
(Figure 15) [Lee & Chung, 2001]. Autophosphorylation of Ser516 within the 
kinase domain was also recently identified, and is required for full kinase 
activation [Schwarz et al, 2003; Wu & Chen, 2003]. Furthermore, mutation of 
this residue prevents radiation-sensitization by Chk2, suggesting a functional 
role for autophosphorylation [Wu & Chen, 2003]. Phosphorylation at Thr68 is 
likely to be the initiating event for dimerization and activation since 
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maintenance of Thr68 phosphorylation is not required for sustained kinase 
activity [Ahn & Prives, 2002]. Phosphorylation of other sites are likely to 
mediate stress specific differences in the extent of kinase activation. Indeed, 
Chk2 purified after gamma radiation, UV, and HU treatment showed different 
kinase activities toward Cdc25C, one of its well validated substrates 
[Matsuoka et al, 1998]. Moreover, the phospho-Thr68 to FHA domain 
intramolecular interaction mechanism may also function in stress induced 
association with other checkpoint proteins. For example, the MDC1 
checkpoint protein FHA domain binds selectively to Chk2 phosphorylated at 
Thr68 [Lou et al, 2003]. The Polo Like Kinase 1 (PLK1), a centrosome-
associated kinase implicated in mitotic progression, can interact with Chk2 
and colocalize with Chk2 at centrosomes. Interestingly, PLK1 can 
phosphorylate residues in the N-terminus of Chk2 including Thr68 [Tsvetkov 
et al, 2003]. The functional import of this interaction for PLK1 or Chk2 
function is not known. The related kinase PLK3 also interacts with Chk2 and 
phosphorylation of Chk2 and PLK3 by one another has been reported [Xie et 
al, 2002, Bahassi et al, 2002]. The subcelluar localization of Chk2 may be 
regulated by another recently described binding protein, karyopherin–alpha2 
[Zannini et al, 2003]. 
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Figure 15. Model of Chk2 Activation. 
A model for gamma irradiation induced formation of active dimmers and monomers. After 
phosphorylation of inactive monomers at T68 by ATM, dimers form and undergo subsequent 
autophosphorylation and may also serve as substrates for other protein kinases. 
Phosphorylated dimers or monomers are active in phosphorylating substrates such as 
Cdc25C. (Adapted from Ahn et al.; DNA Repair, 2004) 
 
 
6.4. Substrates of Chk2 
 
Upon activation Chk2 relays the checkpoint activation signal to a number 
of effectors, which mediate many of the phenotypic characteristics provoked 
by DNA damage including cell cycle arrest and apoptosis (Figure 16). Use of 
oriented peptide libraries has shown Chk2 preferentially phosphorylates a 
consensus motif, L-X-R-X-X-S/T, [O’Neill et al, 2002; Seo et al, 2003]. 
However, these studies may only describe one aspect of Chk2 kinase 
specificity as they do not capture the in vivo complexity of kinase-substrate 
interaction. 
Nevertheless, many functionally important substrates bearing this motif 
have been identified. The first described and best validated of Chk2 
substrates are two members of the cell division cycle 25 dual specificity 
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phosphatase family, Cdc25A and Cdc25C. The Cdc25 family promotes cell 
cycle progression by activation of the cyclin-dependent kinases cdk2 and 
cdk1 through dephosphorylation of inhibitory phosphorylation at Thr14 and 
Tyr15 [Matsuoka et al, 1998; Falck et al, 2001; Brown et al, 1999; Blasina et 
al, 1999]. Cdc25A is destabilized by Chk2 phosphorylation at Ser123 [Falck 
et al, 2001; Sorensen et al, 2003] most likely by increasing susceptibility to 
the SCF_TCRP complex, which mediates Cdc25A turnover [Busino et al, 
2003; Jin et al, 2003]. Chk2 phosphorylation of Ser216 in Cdc25C creates a 
binding site for 14-3-3 proteins  [Zhou et al, 2000] and this interaction is 
thought to result in persistent cytoplasmic Cdc25C localization thus 
preventing the G2/M transition as the cdk1/Cyclin B complex cannot be 
activated [Peng et al, 1997; Dalal et al, 1999]. Taken together, 
phosphorylation of Cdc25A and Cdc25C by Chk2 in response to DNA 
damage explains in part how the checkpoint induces cell cycle arrest. 
Chk2 phosphorylates E2F-1 at Ser364 in response to the DNA-damaging 
agent etoposide, and the modification of that residue regulates both E2F-1 
stabilization and transcriptional activity [Stevens et al, 2003]. Given the 
observation that E2F-1 null thymocytes are resistant to etoposide-induced 
apoptosis [Lin et al, 2001] and that over-expression of E2F-1 can induce cell 
death [DeGregori et al, 1997], modulation of E2F-1 activity represents a 
potentially important pathway through which Chk2 may regulate DNA 
damage-induced apoptosis. 
Two checkpoint pathway scaffold proteins, BRCA1 and Promyelocytic 
Leukemia (PML), can interact with Chk2 and may be phosphorylated by 
Chk2 following DNA damage [Lee et al, 2000; Yang et al, 2002]. 
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Interestingly, both substrates follow a similar pattern in which Chk2 interacts 
with PML and BRCA1 in the absence of DNA damage but following gamma 
irradiation BRCA is phosphorylated at Ser988 and PML is phosphorylated at 
Ser117 in a Chk2-dependent fashion, resulting in subsequent inhibition of 
binding with Chk2. Alanine mutation of either phosphorylation site prevents 
release of Chk2 from BRCA1 or PML after DNA damage suggesting a 
relationship between activation of phosphorylation and inhibition of 
interaction. Functionally, BRCA1Ser988A fails to increase survival of BRCA1-
null HCC1937 cells following IR and BRCA1Ser988A stably expressed in 
HCC1937 cannot mediate double strand break repair [Zhang et al, 2004]. In 
contrast to wild-type PML, the mutant PMLSer117A does not sensitize U937 
leukaemia cells to gamma irradiation- induced apoptosis suggesting 
functional importance for phosphorylation of Ser117 by Chk2. For both 
proteins, a mechanistic understanding of how modification impacts function is 
lacking. For example, it will be of interest to determine if the alanine mutants 
of either protein are able to inhibit downstream functions of Chk2. 
Lukas and colleagues [2003] demonstrated using both fluoresence-loss-in-
photobleaching (FLIP) and fluoresence-return-after-photobleaching (FRAP) 
that unlike other another checkpoint protein Nbs1, Chk2 does not become 
immobilized at sites of damaged DNA but remains soluble after x-irradiation. 
Further, immobilization of Chk2 by fusion to Histone2B inhibits Chk2 function 
leading to the view that Chk2 acts as a “signal spreader” dispersing a 
checkpoint “on” signal to its various substrates implementing cell cycle arrest 
and apoptosis [Lukas et al, 2003]. Given that both PML and BRCA1 form foci 
which collect many checkpoint proteins including Chk2’s principle activator 
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ATM [Xu et al, 2003; Wang et al, 2000], perhaps PML and BRCA1 function in 
part to provide sites of Chk2 activation by ATM. Moreover, Thr68-Chk2 
colocalizes with 53BP1, H2AX, and NBS1 in nuclear foci [Wang et al, 2002; 
Ward et al, 2001]. Once activated therein, Chk2 disengages from the 
complex by phosphorylation of PML, BRCA1, or other factors to then find and 
activate Chk2’s various substrates. Consistent with this model, BRCA1 is 
required for Thr68 phosphorylation by ATM [Foray et al, 2003]. A study, 
which found that closely associated mismatch repair factors (MMR) MSH2 
and MLH1, members of the BASC or BRCA1-associated genome 
surveillance complex [Wang et al, 2000], bind Chk2 and ATM respectively 
and play an important role in Chk2 activation generally supports this 
hypothesis. Restoration of either MSH2 or MLH1 in colon tumor cell lines 
bearing mutations in these factors enhances Thr68 phosphorylation after 
DNA damage, restores Cdc25A destabilization by gamma irradiation, and 
complements the RDS phenotype, all hallmarks of increased Chk2 signaling 
[Brown et al, 2003]. Also, Chk2 from MSH-/- cells does not undergo Thr68 
phosphorylation after gamma irradiation [Franchitto et al, 2003]. Moreover, 
Chk2 activation is defective in cells derived from Nijmegen Breakage 
Syndrome patients who carry inactivating mutations in Nbs1 a component of 
the Mre11–Rad50–Nbs1 complex which plays central role in DNA repair and 
is required for ATM activation after DNA damage [Buscemi et al, 2001; Usui 
et al, 2001; Uziel et al, 2003; Carson et al, 2003; Lee et al, 2003; Mochan et 
al, 2003] 53BP1 another checkpoint factor important in forming DNA damage 
signaling complexes with ATM and BRCA1 may also play a role in Chk2 
activation. 53BP1 null MEFs show little if any defect in Chk2 phosphorylation 
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as determined by mobility shift in polyacrylamide gels after IR [Ward et al, 
2003; Fernandez-Capetillo et al, 2002] but focus formation of activated Chk2 
as detected by an anti-phosphoT68 Chk2 antibody is compromised by 53BP1 
knockdown [Wang et al, 2002]. Interestingly, 53BP1 is involved in the 
phosphorylation of other ATM substrates including Smc1 [DiTullio et al, 
2002]. Also, Chk2 activation is independent of H2AX which is phosphorylated 
at sites of DNA damage [Fernandez-Capetillo et al, 2002]. A more recently 
discovered checkpoint factor also present in damage foci, NFBD1/MDC1 
binds to phospho-Chk2 but its requirement for Chk2 Thr68 phosphorylation is 
controversial [Lou et al, 2003; Stewart et al, 2003; Goldberg et al, 2003; Peng 
& Chen, 2003; Shang et a., 2003]. Detailed understanding of how the various 
signaling interactions required for Chk2 activation are integrated will be of 
great interest. 
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Figure 16. The Chk2 network. 
Chk2 integrates signals from upstream kinases and binding partners to phosphorylate key 
targets involved in cell cycle checkpoints.  
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6.5. Chk2 knockout mice and p53 connection 
 
Given the central role of both p53 and Chk2 in cell cycle arrest and 
apoptosis as well as their roles in tumor suppression, many reports have 
described connections between Chk2 and p53. Conclusions from several 
studies, however, have led to the realization that different approaches can 
provide widely varying results. Several groups placed Chk2 immediately 
upstream of p53 through studies involving Chk2 knockout mice as well as in 
vivo and in vitro experiments. Phosphorylation of p53 at Ser20 had been 
suggested to be a critical event for stabilizing p53 [Shieh et al, 1999; Unger 
et al, 1999]. The search for a kinase capable of Ser20 phosphorylation 
seemed to end when it was reported that Chk2 could phosphorylate p53 at 
Ser20 in vitro and this event was sufficient to disrupt pre-complexed p53 and 
Mdm2 [Shieh et al, 2000; Chehab et al, 2000]. Introduction of a dominant 
negative Chk2 led to failure of U2OS cells to stabilize or phosphorylate 
endogenous p53 at Ser20 and Chk2 enhanced a p53 dependent G1 
checkpoint [Chehab et al, 2000]. In another study, it was reported that 
immunoprecipitated Chk2 is activated by IR to phosphorylate p53 and 
overexpression of Chk2 enhances the ability of p53 to transactivate a p53 
responsive reporter plasmid [Falck et al, 2001]. Interestingly, Chk2 
downregulation by antisense in 293 cells increases sensitivity to DNA double 
strand breaks [Yu et al, 2001]. Silencing of Chk2 by novel engineered zinc 
finger transcription factors decreases p53 transcriptional activation of the 
MDM2 gene and reduces p53 Ser20 phosphorylation [Tan et al, 2003]. 
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However, other work has weakened the view that Chk2’s regulation of p53 
is generally applicable. First, the region on p53 spanning Ser20 does not 
share homology with the consensus motif, L-X-R-X-X-S/T present in other 
known substrates of Chk2 and a peptide covering the p53 Ser20 region is a 
poor Chk2 substrate [O’Neill et al, 2002; Seo et al, 2003]. Interestingly, two 
regions of p53, aa 117–132 and aa 272–288, are proposed to provide Chk2 
docking sites to allosterically regulate the kinase activity toward p53 and 
purified Chk2 supplemented with these docking-site motifs phosphorylated a 
Ser20 peptide by kinase assay [Craig et al, 2003]. A second group has 
identified another Chk2 binding domain in p53 centering on Thr329 [Qin et al, 
2003]. In contrast to this work, Chk2 purified from tumor cell lines before and 
after DNA damage could not phosphorylate different forms of truncated or 
full-length p53 even though it was markedly activated to phosphorylate the 
domain of Cdc25C containing Ser216 [Ahn et al, 2003]. Experiments in vivo 
similarly challenge the Chk2–p53 relationship. Introduction of Chk1 and Chk2 
siRNAs into several human tumor cell lines failed to affect p53 stabilization, 
Ser20 phosphorylation or transcriptional activity despite preventing Ser216 
phosphorylation of Cdc25C [Ahn et al, 2003]. Even more, homozygous 
deletion of Chk2 in HCT-116 colon carcinoma cells yielded no phenotype 
with respect to p53, G1 or G2 cell cycle arrest, and apoptosis [Jallepalli et al, 
2003]. 
Two independently generated Chk2 knockout mice have supported a role 
for Chk2 in the regulation of p53 but diverge in their findings and proposed 
mechanisms. The first reported Chk2 null mouse from Hirao and colleagues 
[Hirao et al, 2000] strikingly showed that thymocytes, splenic T cells, and 
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MEFs lacking Chk2 are unable to stabilize p53 following gamma irradiation 
and this defect is corrected by reintroduction of Chk2. These cells are highly 
resistant to apoptosis consistent with a defect in p53 signaling [Hirao et al, 
2000]. A follow up study showed that Chk2 mice are highly resistant to 
apoptosis in multiple tissue compartments by whole body irradiation 
experiments and develop chemically-induced skin tumors more rapidly [Hirao 
et al, 2002]. The G1/S checkpoint of these mice is compromised at low doses 
of gamma irradiation but cells arrest normally at doses above 5Gy. 
Interestingly, however, p53 null mice do not show any dose dependency in 
the same assay. In contrast to the original report a second study from this 
group showed that gamma irradiated Chk2-/- thymoctyes show a defect in 
transcriptional activation of Bax but only a slight depression in p21 
upregulation [Hirao et al, 2002]. 
A different group using MEFs from these same mice, however, found no 
defect in G1/S arrest or p21 mRNA induction at even low X-ray doses [Jack 
et al, 2002]. More recently a second Chk2 knockout mouse generated by 
another group was reported with somewhat different results [Takai et al, 
2002]. Consistent with the first Chk2 null mouse, the second was resistant to 
apoptosis induced by gamma irradiation in many tissues strongly implicating 
Chk2 in DNA damage induced apoptosis [Takai et al, 2002]. 
No G2 or S-phase checkpoint defect was detected but these authors did 
observe a deficient G1/S arrest consistent with impaired p53 signaling. In 
contrast to Hirao et al, they reported only a 30–50% reduction in p53 
stabilization and human p53 introduced into Chk2-/- MEFs was 
phosphorylated normally on Ser20 after IR, indicating that in murine tissue 
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Chk2 makes a partial contribution to p53 stabilization but other factors clearly 
contribute. Perhaps the most striking result with respect to p53 was that, 
despite only a partial p53 stabilization defect, upon analysis of five p53 
targets genes by quantitative RT–PCR in thymocytes and MEFs, the authors 
saw no mRNA upregulation in the Chk2-/- cells after IR providing a possible 
mechanistic explanation for the G1/S arrest and apoptotic defects in these 
cells [Takai et al, 2002]. However, the relationship between Chk2 and p53 is 
likely to be stimuli–as well as cell type-specific as cell death in primary 
neuronal cultures induced by etoposide or camptothecin was shown to be 
ATM-dependent but Chk2 independent [Keramaris et al, 2003]. 
To summarize the mouse studies to date, it is clear that Chk2 plays a central 
role in gamma irradiation induced apoptosis however the mechanism is 
unclear. Chk2 likely regulates p53 transcriptional activity independently of 
Ser20 phosphorylation or even stabilization in murine tissues after IR, but in 
other contexts yet to be described signaling pathways play a central role. It 
remains to be determined when Chk2 regulates p53, in what context, and 
what factors mitigate or compensate for Chk2 in cases where it is not 
required. 
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6.6. Targeting DNA damage checkpoint kinases as anticancer 
treatment 
 
Radiation therapy and chemotherapy have been used as important 
modalities for anti cancer treatment for decades. It is likely that they will 
remain in use for anti cancer therapy in the foreseeable future. Their central 
function is to damage DNA. The damaged DNA will immediately activate the 
DDR network, and thus hamper the desired effects, while cancer growth 
arrest and apoptosis are major outcomes desired in drug treatment. Since 
damage to DNA might be the common underlying mechanism for the positive 
outcome of anticancer therapy, an important issue emerging in drug 
discovery is to target anticancer treatments on cell cycle checkpoints. 
Recently, we could show that besides the epigenetic regulation of the 
p21WAF1 promoter [Habold et al, 2008], G2 checkpoint arrest is not only 
induced trough the checkpoint kinase Chk1, but early Chk1 activation also 
directs senescence and mitotic catastrophe – two main strategies to long-
term affect the growth of tumor cells – even in recovery from G2 checkpoint 
arrest [Poehlmann et al, 2011]. Furthermore, inhibition of important 
molecules in the DNA damage response network has increasingly been 
considered as an innovative strategy for improving the effects of 
chemotherapy and radiation therapy [Janetka et al, 2007; Bulavin et al, 2001; 
Tao & Lin, 2006]. Significant experience in this field was already gained in 
the 1990s. At that point of time, it could be shown that caffeine is an inhibitor 
of ATM and ATR [Sarkaria et al, 1999]. However, the high dosage of caffeine 
required for this function cannot be applied to humans. 
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Chk1 with its central function in DNA damage response pathways has also 
been considered as an appropriate target for inhibition strategies. In the last 
several years, a large number of chemical inhibitors to Chk1 have been 
developed [Janetka et al, 2007]. These substances inhibit, in addition to 
Chk1, a variety of kinases, including Chk2. The therapeutic possibilities of 
targeting Chk1 are discussed in a recent review [Janetka et al, 2007]. The 
possibilities and also problems caused by applying Chk2 inhibitors as 
therapeutic approach in clinical oncology have recently been reviewed by 
Antoni et al. [2007]. To optimize the effects of chemotherapy and radiation 
therapy, inhibitors to a larger number of other checkpoint kinases are also 
being developed. 
In addition, because of its importance in cancer, the ERK pathway has 
been a focus for drug discovery, but rather with Ras, Raf, and MEK as the 
main targets [Downward, 2003] and [Kohno & Pouyssegur, 2006]. 
Furthermore, inhibition of p38 activity causes enhanced apoptosis in 
response to DNA-damaging agents, such as doxorubicin and cisplatin, as 
well as microtubule-disrupting agents, such as taxol, vicristine, and 
vinblastine [Deacon et al, 2003; Lee et al, 2006; Losa et al, 2003]. In this 
context, also JNK inhibitors have been considered for anticancer therapy, 
and this is linked to their ability to interfere with DNA repair in response to 
genotoxic drugs [Kennedy et al, 2003]. However, as JNK may also have a 
tumor suppressor function due to its ability to promote apoptosis, JNK 
inhibitors would then prevent apoptosis, and thus the usefulness of JNK 
inhibitors is still under discussion. 
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6.7. Exploiting CHEK2 genetics in cancer treatment 
 
A key issue now is whether our current knowledge about CHEK2 and 
tumour susceptibility can be used to help treat patients with cancer. Testing 
most cancer patients for mutations in CHEK2 is probably not yet appropriate, 
as the evidence indicates that CHEK2 on its own does not predispose to 
cancer. However, if it is correct that CHEK2 mutations are associated with an 
increased risk of contralateral breast cancer and with breast cancer 
developing from benign tumours after radiotherapy, knowing the CHEK2 
status of such patients might help in their management. Finally, is it possible 
to exploit the loss of CHK2 function as a therapeutic strategy? One possibility 
may be the use of poly(ADP-ribose) polymerase (PARP) inhibitors in cancer 
patients who carry somatic but not germline mutations in CHEK2, as it has 
been reported that tumour cells that are functionally deficient for CHK2 are 
sensitive to PARP inhibition109. Indeed, PARP inhibitors are currently being 
evaluated as a cancer therapy in those individuals who are deficient for BR 
CA1 and BRCA2, which function in the same repair pathway as CHK2. 
 
 
6.8. Drugs targeting CHK2: inhibition or activation? 
 
There is currently a debate over the most appropriate way to target CHK2 
in tumours that harbour the wild type form of this kinase. Among the issues 
are questions of compound selectivity and the potential for combination with 
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DNA-damaging chemotherapy and radiotherapy. At the cellular level it is 
necessary to take account of the different molecular lesions caused by 
different DNA-damaging agents, which elicit distinct responses from the 
CHK2 pathway. The context of intervention is also important, particularly the 
tumour genetic background such as p53 mutational status. The level of 
intrinsic DNA damage in a given tumour cell type and the degree to which 
CHK2 functions might be essential for maintenance of the transformed 
phenotype have to be considered. In circumstances of high intrinsic DNA 
damage, a CHK2 inhibitor might have the potential for single-agent efficacy. 
However, in tumours where activated CHK2 contributes directly to the 
malignant phenotype or to resistance to DNA-damaging agents, a 
combination of a CHK2 inhibitor with a DNA-damaging agent might lead to an 
increased therapeutic index. There are also suggestions that hyperactivation 
of CHK2 pathways, in the absence of extrinsic DNA-damaging agents, would 
be effective for inducing certain tumour cells into senescence or even 
apoptosis. 
 
 
6.8.1. Inhibition of CHK2 
There are several lines of evidence that suggest that CHK2 inhibition in 
combination with genotoxic agents (IR and chemotherapeutics) might have 
therapeutic value. Inhibition of CHK2 expression has been found to attenuate 
DNA damage-induced cellcycle checkpoints and to enhance apoptotic 
activity in HEK293 cells [Rose et al, 2001]. CHK2 inhibition has also shown 
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activity in two cellular models of mitotic catastrophe, indicating a potential for 
chemosensitization with doxorubicin [Castedo et al, 2004]. 
In a recent report, targeting of CHK2 using small interfering RNA or a 
dominant-negative form of this kinase (CHK2-DN) prevented survivin release 
from the mitochondria and enhanced apoptosis following DNA-damage by IR 
or doxorubicin [Ghosh et al, 2006]. In addition, the conditional expression of 
CHK2-DN showed potentiation of doxorubicin cytotoxicity in the HCT116 
colon carcinoma cell line grown as a xenograft in mice. It should not be 
overlooked, however, that several studies have reported no therapeutic value 
of CHK2 inhibition. In particular, it has been reported that loss of CHK2 
function has no additional therapeutic benefit compared with loss of CHK1 
alone when combined with the antimetabolites 5-fluoro-2-deoxyuridine and 
gemcitabine [Morgan et al, 2006]. Similarly, small interfering RNA studies in 
two cancer cell lines have led to the proposal that CHK1 is the only 
checkpoint kinase that is relevant as a drug target [Xiao et al, 2006]. In part, 
this underscores the difficulty of reconciling results from multiple cell line 
models, using non-equivalent DNAdamaging agents and different strategies 
for inhibition of CHK2 function. It may be that complete validation of this 
target in the context of cell killing in vitro and in vivo must await 
pharmacological studies with selective smallmolecule inhibitors of CHK2 in 
tumours of defined genetic background. 
To date, all reported inhibitors of CHK2 target the ATP-binding pocket of 
this kinase. This is not surprising as most compounds have been identified 
through screening for inhibitors of the catalytic activity of this protein. As a 
result, CHK2 inhibitors tend to inhibit other kinases in addition to their primary 
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target, and in particular the functional relative, CHK1. This has meant that the 
difficulty of examining the CHK2- dependent pathways separately from 
CHK1-mediated responses has been a recurrent theme in the 
pharmacological validation of CHK2 as a drug target. For example, the dual 
CHK1 and CHK2 inhibitors Go6976 and EXEL-9844 (currently in clinical 
trials) showed effects in cellular assays that are also seen with loss of CHK1 
alone and so it is not possible to ascertain from these studies the 
independent effect of CHK2 inhibition [Kohn et al, 2003; Matthews et al, 
2007]. 
The advent of selective inhibitors of CHK2 promises to address this 
problem and the recent publication of the X-ray crystal structure of the CHK2 
kinase domain will be useful in the development of additional chemical 
classes of CHK2-selective inhibitors [Oliver et al, 2006]. A recent report 
identified a series of bis-guanylhydrazone compounds as potent CHK2 
inhibitors using in vitro kinase assays [Jobson et al, 2007], although these 
inhibitors did not show inhibition of CHK2 in cells and might suffer from 
confounding off-target activities or poor cell permeability. In addition, a series 
of isothiazole carboxamides has provided selective (versus CHK1) CHK2 
inhibitors, such as VR X0466617 [Larson et al, 2007; Carlessi et al, 2007]. 
This small molecule clearly blocked CHK2 activity in cells, but did not 
significantly change the cell-cycle distribution or prevent the G2/M arrest in 
short-term culture of normal or irradiated cells. In longer-term culture (>6 
days) exposure of normal cells to VR X0466617 alone led to an 
antiproliferative effect, but the possibility that this was a manifestation of an 
off-target activity could not be ruled out. Evaluation of this compound in 
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combination with doxorubicin or cisplatin showed no potentiation of 
cytotoxicity. It should be noted, however, that the combination studies were 
performed in the MCF-7 cell line, which harbours wild-type p53. It will 
therefore be interesting to test whether selective and potent inhibitors of 
CHK2 potentiate cytotoxic treatments in p53-deficient cell lines. 
One therapeutic strategy in which inhibition of CHK2 has clear value is 
radioprotection. As discussed earlier, targeted disruption of Chk2 in irradiated 
mice leads to increased survival through the suppression of apoptosis [Takai 
et al, 2002; Hirao et al, 2000; Hirao et al., 2002; Jack et al, 2002]. This led to 
the hypothesis that targeting CHK2 with a small-molecule inhibitor might 
suppress the side effects of radiotherapy, which is administered to 
approximately 50% of all cancer patients. The first pharmacological validation 
of this therapeutic strategy came with a report on a series of selective ATP-
competitive 2-arylbenzimidazole CHK2 kinase inhibitors, which were 
developed as radioprotective agents for normal proliferating tissues [Arienti et 
al, 2005]. A potent 2-arylbenzimidazole prevented γ-irradiation-induced 
apoptosis of CD4+ and CD8+ human T cells isolated from blood at doses 
consistent with the biochemical measurement of CHK2 inhibition. This 
radioprotective effect has also been reported with the structurally distinct VR 
X0466617 CHK2 inhibitor in isolated mouse thymocytes [Carlessi et al, 
2007]. The observation of radioprotection of normal cells with two distinct and 
selective CHK2 inhibitors suggests that this is a promising therapeutic 
context to pursue. 
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6.8.2. Activation of CHK2  
 
As an alternative to CHK2 inhibition, there may also be circumstances 
where activation of this kinase could have therapeutic value. CHK2 clearly 
has a role in the barrier to oncogenesis and its activation in the absence of 
DNA-damaging agents may force tumour cells to exit the proliferative state, 
either through death or senescence. In a study investigating this 
experimental therapeutic approach [Chen et al, 2005], involved stable 
transfection of p53-deficient DLD1 colon cancer and HeLa cervical carcinoma 
cell lines with a tetracycline-inducible form of CHK2. On induction, CHK2 was 
produced in both cell lines and activated owing to phosphorylation at T68 in 
the absence of DNA-damaging agents, perhaps due to a background level of 
constitutive DNA damage or through oligomerization of the protein [Oliver et 
al, 2006]. The increased levels of activated CHK2 led to decreased cell 
proliferation, G2 arrest and increased apoptosis. 
Additionally, by eye the cells looked senescent. Thus, manipulation of 
CHK2 activation, for example, through inhibition of the PPM1D/WIP1 
phosphatase (which antagonizes CHK2 activation through T68 
dephosphorylation) might have therapeutic benefit. However, a note of 
caution is needed as this study involved overexpression of CHK2 and so it 
may be that only the introduction of large quantities of CHK2 into cells and 
not chemical activation of the endogenous kinase will allow senescence or 
death. Altogether, cellular and pharmacological studies demonstrate that the 
response of a tumour to CHK2 manipulation will depend on a specific cellular 
context. Given that many tumour cells exhibit high levels of intrinsic DNA 
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damage, the functional availability of the DNA-damage response and repair 
components will dictate the therapeutic outcomes of CHK2 inhibition or 
activation. This is exemplified by a recent study showing that 
pharmacological inhibition of the repair machinery in combination with IR 
results in increased activation of CHK1 and CHK2 [Sturgeon et al, 2006]. 
Consequently, the ability of checkpoint inhibitors to abrogate the G2 arrest 
and sensitize these cells to IR was reduced compared with their activity in 
irradiated cells not exposed to inhibitors of DNA repair. These results 
highlight the importance of considering the balance of all components in the 
CHK2 pathway: the levels of DNA damage, the degree of signalling through 
CHK2 and the efficiency of DNA repair in response to checkpoint activation. 
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Chapter 2 
AIM OF THE STUDY 
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Survivin is a pivotal cancer gene with multiple roles in cell viability and 
mitosis, but the function(s) of its alternatively spliced isoforms has remained 
elusive.  
Transcription of the survivin locus is complex, giving rise to at least five 
mRNA species that encode, in addition to wild type (WT) survivin, the 
variants survivin-2B, -3β, -2α and -∆Ex-3. Structurally, survivin-2α and -3B 
are generated by “read-through” into intron 2, or via inclusion of an 
alternative exon 3B, whereas survivin-2B and -∆Ex3 originate from the 
insertion of an alternative exon 2B , or the skipping of exon 3, respectively. 
Elucidating the function(s) of the survivin spliced variants has not been 
straightforward, complicated by the low levels of expression of these 
molecules in most cells, and the limited availability of specific reagents that 
discriminate between the different isoforms. For instance, survivin-2B has 
been reported to promote apoptosis, in vitro. However, low levels of survivin-
2B correlate with better survival in acute myeloid leukemia, and its silencing 
in ovarian cancer has been linked to enhanced sensitivity to taxanes in 
resistant tumors. A role of the survivin isoforms in mitosis has been equally 
controversial, as this function has been proposed in some reports, but 
negated in others. 
 
In this study, we took a multidisciplinary approach of genome-wide 
bioinformatics, analysis of the DNA damage response and evaluation of 
primary patient samples, to dissect a potential role of survivin-∆Ex3 in 
cancer. 
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Chapter 3 
MATERIAL & METHODS 
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1. Drugs 
 
Cycloheximide, camptothecin and etoposide were purchased from Sigma 
(Saint Louis, Missouri, USA).  
 
 
 
1.1. Cycloheximide Preparation 
 
To obtain a 2 mg/ml cycloheximide stock solution, 10 ml of sterile water 
were added to 20 mg cycloheximide powdered stock and the drug was 
completely dissolved, stored at -20°C and diluted i n complete culture medium 
immediately before use. 
 
 
1.2. Camptothecin Preparation
 
 
To obtain a 5 mg/ml camptothecin stock solution, 10 ml of DMSO were 
added to 50 mg camptothecin powdered stock and the drug was completely 
dissolved, stored at -20°C and diluted in complete culture medium 
immediately before use. 
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1.3. Etoposide Preparation 
 
To obtain a 5 mg/ml etoposide stock solution, 10 ml of PBS were added to 
50 mg etoposide powdered stock and the drug was completely dissolved, 
stored at -20°C and diluted in complete culture med ium immediately before 
use. 
 
 
2. Human Tumour Cell Lines 
 
The human lung adenocarcinoma (H460), breast adenocarcinoma (MDA-
MB-431 and MCF-7), glioblastoma (LN229), and colorectal adenocarcinoma 
(HCT116 and SW480) cell lines were purchased from the American Type 
Culture Collection (ATCC, Manassas, VA). 
The colorectal adenocarcinoma cell line HCT116 containing the DR-GFP 
construct was kindly provided by Dr. S. Powell (Memorial Sloan Kettering 
Center, New York, NY). 
 
 
2.1. Human Tumour Cell Lines Growth Conditions
 
 
All cell lines were maintained as monolayers in 100x20mm Petri Dish 
(Corning, Pittsburgh, PA, USA) at 37°C in a 5% CO 2 humidified atmosphere 
in an air incubator (Thermo Fisher Scientific, Pittsburgh, PA, USA). 
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H460 were maintained in RPMI-1640 medium (Invitrogen, Grand Island, 
NY, USA), supplemented with 10% (v/v) FBS. LN229, MDA-MB-431 and 
MCF-7 cells were cultured using D-MEM medium (Invitrogen), supplemented 
with 5% (v/v) FBS. HCT116 were maintained in Mc Coy’s 5a medium 
(Invitrogen), supplemented with 10% (v/v) FBS and SW480 were cultered 
using Leibovitz’s L-15 medium supplemented with 10% (v/v) FBS. 
All tumour cells were cultured as follow: at set time points, specific growth 
medium was removed from the 100x20mm Petri Dish and the cell monolayer 
was washed twice with 5 ml 37°C-heated PBS. One ml of a Trypsin-EDTA 
solution (Invitrogen) was then added to each dish. After a 5 minutes-
incubation at 37°C with gentle shaking, cell detach ment was checked under 
the microscope (Micromaster, Fisher Scientific, Pittsburgh, PA, USA) and 
trypsin activity was blocked by addition of 5 ml of complete medium. Five ml-
suspension containing detached cells was transferred in a sterile 15 ml 
conical tube (Falcon-Fisher Scientific) and centrifuged at 1,500 rpm for 
5 minutes at room temperature in a Beckman GS-6R refrigerated centrifuge 
(Beckman, Danvers, MA, USA). Cell pellet was then carefully resuspended in 
5 ml of growth medium and a small aliquot (10 µl) was checked under the 
microscope in a Burker camera, and the number of detached cells was 
calculated by counting the number of cells after Trypan blue coloration. 
Frozen stocks of human tumour cell lines were prepared as follows. Cells 
in logarithmic growth phase were detached from the dishes and counted as 
previously described. The percentage of viable cells was also determined by 
Trypan blue dye exclusion test by mixing, in a 0.5 ml clean conical tube 
(Eppendorf – Fisher Scientific) 5 µl of detached cells suspension, 45 µl of 
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PBS and 50 µl of Trypan blue dye (Invitrogen). Five µl of Trypan blue dye-
stained cell suspension were placed onto a Burker camera and checked 
under the microscope. The number of viable cells generally exceeded 95%. 
After counting, the cell suspension was centrifuged at 1,500 rpm for 5 
minutes at 4°C. The supernatant was removed and the  cell pellet was 
carefully resuspended in 4°C-cold freezing medium [ D-MEM/F12 medium 
supplemented with 40% (v/v) FBS] at a density of 5 x 106 viable cells/ml. One 
ml of such a cell suspension was then transferred in a 2 ml sterile Nalgene 
tube (Nalgene Company, Rochester, NY, USA) and placed on ice. One ml of 
cryoprotective medium [basal EAGLE’S medium with HANKS’ BBSS and 
15% (v/v) dimethylsulfoxide (DMSO)] (Invitrogen) was added to each tube 
and after a gentle resuspension, the tube was placed onto a Cryo 1°C 
Freezing Container (Nalgene) and stored at –80°C fo r the initial freezing 
step. After 16-24 hours, frozen cells were removed from the freezing 
container and stored under liquid nitrogen vapours in the 
Barnstead/Thermolyne containers (Barnstead/Thermolyne, Dubuque, IO, 
USA).  
For cell thawing, frozen cells were incubated in a 37°C water bath 
(Thermo Fisher Scientific), transferred into a sterile 15 ml conical tube 
containing 10 ml of complete growth medium and centrifuged at 1,500 rpm 
for 5 minutes at room temperature. The cell pellet was then resuspended in 
15 ml of growth medium and cells were seeded in a 100x20mm Petri Dish. 
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3. Nucleic Acids Quantification 
 
Concentration and quality of solutions containing DNA, RNA or 
oligonucleotides were determined by spectrophotometric analysis as follows. 
In two clean 1.5 ml tube (Eppendorf), a suitable volume of nucleic acid-
containing solution (generally, 5 and 10 µl) was gently mixed with RNase- or 
DNase-free distilled water to a final volume of 200 µl to obtain a 1:40 and 
1:20 dilutions. As the blank sample, a third clean tube containing 200 µl of 
RNase- or DNase-free distilled water was also prepared. The content of each 
tube was transferred into quartz cuvettes (Fisher Scientific), the cuvettes 
were then placed onto a Lambda 11/Bio spectrophotometer (Fisher 
Scientific) and absorbance values at 260 nm (A260nm) and 280 nm (A280nm) of 
wave length were measured. The A260nm and A280nm values obtained with the 
blank sample were subtracted from the absorbance values obtained with the 
nucleic acid-containing samples, and DNA, RNA or oligonucleotide 
concentration was then calculated using these formulae: 
 
µg/ml of DNA = (A260nm) x (DILUTION FACTOR) x (50 µg/ml) 
µg/ml of RNA = (A260nm) x (DILUTION FACTOR) x (40 µg/ml) 
µg/ml of oligonucleotide = (A260nm) x (DILUTION FACTOR) x (30 µg/ml) 
 
The nucleic acid concentration was expressed as the mean of the values 
(µg/ml) obtained in the two independently-prepared and –measured dilutions. 
The quality of nucleic acid solutions was evaluated by calculating the 
A260nm/A280nm ratio. It is well known that for both DNA and oligonucleotide, a 
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ratio of 1.8-2 was indicative of a good-quality preparation, whereas high 
quality RNA solutions are characterised by a A260nm/A280nm ratio of 2. 
 
 
4. Protein Concentration Determination 
 
Protein concentration was determined according to Bradford [1976]. 
 
 
4.1. Calibration Curve Preparation 
 
Solutions of bovine serum albumin (BSA) (0.001 µg/µl, 0.0025 µg/µl, 
0.005 µg/µl, 0.01 µg/µl, 0.025 µg/µl and 0.05 µg/µl) were prepared by 
dissolving powdered BSA (Sigma) in distilled water. In a 1.5 ml tube, 250 µl 
of each BSA solution were mixed with 150 µl of distilled water and 100 µl of 
Biorad Protein assay dye (Biorad, Hercules,CA, USA). In the blank sample, 
400 µl of distilled water were mixed with 100 µl of Biorad Protein assay dye. 
Samples were rapidly transferred into disposable 96 well plate (Corning-
Costar) and the absorbance at 595 nm wave length of each calibration point 
was measured using a microtiter plate reader (Fisher Scientific). The 
absorbance value corresponding the blank sample was then subtracted from 
the values obtained in the BSA-containing samples. Each calibration sample 
was run in triplicate.  
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4.2. Proteins Concentration Quantification 
 
Concentration of extracted proteins was determined by mixing in a 1.5 ml 
tube 5 µl of protein extracts with 95 µl of Biorad Protein assay dye and 
distilled water to a final volume of 500 µl. Samples were rapidly transferred 
into 96 well plate and the absorbance at 595 nm wave length was measured 
in the spectrophotometer plate reader. From the calibration curve, it was 
possible to determine the protein concentration of each sample. Also in this 
case, each sample was run in triplicate.  
 
 
5. Agarose Gel Preparation 
 
All agarose gel electrophoresis experiments were carried out using Hoefer 
horizontal electrophoresis units (Biorad). 
Gels of different sizes and percentages (w/v = grams of powdered agarose 
per 100 ml of running buffer) were prepared in clean glass bottles by mixing 
suitable amounts of powdered agarose (Sigma) in 1x TAE [0.04 M Tris-
Acetate (Sigma), 0.001 M EDTA (Sigma)] or 1x TBE [0.09 M Tris-Borate 
(Sigma), 0.002 M EDTA] running buffers. Agarose was dissolved by heating 
in a microwave, cooled to about 50°C, transferred o nto the casting tray and, 
after the insertion of a clean comb, left to polymerise at room temperature. 
When polymerisation was completed, the comb was removed and solidified 
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agarose gel was transferred into the running tray and submerged with 
running buffer. 
 
 
6. SDS-Polyacrylamide Gel Preparation 
 
All SDS-polyacrylamide gels used for protein separation (8 centimetres 
high/ 10 centimetres length/ 1 millimetres thick) were prepared as described 
by Laemmli [1970] and run in a vertical electrophoresis slab unit (Biorad). 
Resolving gel (10 ml) was prepared in a 15 ml conical tube (Falcon-Fisher 
Scientific) by mixing a suitable volume of 40% (w/v) polyacrylamide stock 
solution (acrylamide:N,N'-methylenebisacrylamide molar ratio = 29:1) 
(Sigma) with 0.1 ml of 10% (w/v) SDS solution (Sigma) [final concentration = 
0.1% (w/v)], 2.5 ml of 1.5 M Tris-HCl pH 8.8 solution (Sigma) (final 
concentration = 375 mM), 100 µl of 10% (w/v) APS (Sigma) [final 
concentration = 0.1% (w/v)] and 6 µl of TEMED (Sigma) [final concentration = 
0.06% (v/v)], and subsequently poured into the gap between glass plates 
(previously washed with absolute ethanol) leaving sufficient space for the 
stacking gel. The poured resolving polyacrylamide gel solution was 
immediately and carefully overlaid with 0.1% (w/v) SDS solution (the overlay 
prevents oxygen from diffusing into the gel and inhibiting polymerisation) and 
the gel was placed in a vertical position at room temperature to polymerise. 
When polymerisation was complete (within 20-40 minutes), the overlay was 
poured off and the top of the gel was carefully washed several times with 
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distilled water to remove any unpolymerised acrylamide. The stacking gel (2 
ml) containing 5% (w/v) polyacrylamide (acrylamide:N,N'-
methylenebisacrylamide molar ratio = 29:1), 0.1% (w/v) SDS, 125 mM Tris-
HCl pH 6.8, 0.1% (w/v) APS and 0.1% (v/v) TEMED was prepared in a 15 ml 
conical tube and poured directly onto the surface of the polymerised 
resolving gel. A clean comb was immediately inserted into the stacking gel 
solution and the gel was placed in vertical position to polymerise. When 
polymerisation was complete, the comb was removed, the wells were 
washed with distilled water to remove any unpolymerised acrylamide and the 
gel was mounted in the electrophoresis apparatus containing TGS running 
buffer [25 mM Tris base, 250 mM Glycine (Sigma), 0.1% (w/v) SDS, pH 8.3] 
in both upper and lower buffer reservoirs. 
 
 
7. Preparation of the Plasmid Vectors 
 
To obtain a permanent and stable source of pcDNA3 (Invitrogen, San 
Diego, CA, USA), pGEX4T (Invitrogen), survivin-cDNA, survivin-∆Ex3 cDNA 
vectors, the following procedures were performed. 
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7.1. Transformation of Bacteria 
 
In an ice-cold 1.5 ml Eppendorf tube, 50 µl of competent bacterial cells 
(DH5α, Invitrogen) were mixed with 50 ng (5 µl). The mixture was gently 
mixed by tapping and the tube was chilled on ice for 30 minutes, incubated 
for 20 seconds at 42°C in a water bath and for 2 mi nutes on ice. After a 5-
minute incubation at room temperature, 900 µl of LB medium were added 
and tube was placed into a 37°C-heated shaking incu bator at 225 rpm for 2 
hours. The tube was then centrifuged at 3,000 rpm for 5 minutes at room 
temperature, 950 µl of supernatant LB were removed and bacterial cell pellet 
was resuspended in the remaining 50 µl, plated onto 90-mm dish (Corning-
Costar) containing selective solid LB medium [liquid LB medium, 1.5% (w/v) 
agar (Invitrogen), 50 µg/ml ampicillin (Sigma)] and incubated over night at 
37°C. Each colony, representing ampicillin-resistan t/transformed growing 
bacterial cells, was picked-up with a sterile disposable loop, dissolved in a 
50 ml conical tube containing 10 ml of liquid LB medium supplemented with 
ampicillin (50 µg/ml final concentration) and allowed to grow over night 
at 37°C with 225 rpm shaking.  
 
 
7.2. Small Scale Preparation of Plasmid DNA (“miniprep”) 
 
To confirm the presence of plasmids in ampicillin-resistant liquid culture, 
8 ml of the bacterial suspension were used for “miniprep” by using Qiagen 
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Plasmid Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's 
instructions. Plasmid DNA concentration was determined 
spectrophotometrically as described in the section 1.3. 
Electrophoretic analysis was performed on 1% (w/v) agarose mini gel 
prepared and run in 1x TAE buffer. About 500 ng of extracted and original 
DNA vectors were loaded and separated at 90 volt (SE300 power supply; 
Amersham) at room temperature for 1 hour in the presence of 500 ng of λ-
BsteII molecular weight marker (Sigma). DNA fragments were visualised by 
placing the gel onto the UV-transilluminator (260 nm wave length) (Biorad) 
after a 30-minutes staining with 1 µg/ml ethidium bromide (Invitrogen)-1x 
TAE buffer staining and a 30-minute 1x TAE buffer destaining. 
 
 
7.3. Storage of Vector Transformed Bacteria 
 
In a 2 ml sterile Nalgene tube, 1.6 ml of ampicillin-resistant liquid bacterial 
culture and 0.4 ml of sterile pure glycerol (final concentration (v/v) = 20%) 
were mixed by a vortex mixer and frozen by snap freezing in liquid nitrogen 
and stored at -80°C. 
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7.4. Large Scale Preparation of Plasmid DNA (“maxiprep”) 
 
By means of a sterile spatula, frozen bacterial cells were scraped from the 
2 ml sterile Nalgene tube and dissolved in 10 ml of 50 µg/ml ampicillin 
containing-LB medium (contained in a 50 ml conical tube) and allowed to 
grow at 37°C in a shaking incubator at 225 rpm. Aft er 8 hours, 10 ml liquid 
culture was mixed with 100 ml of fresh 50 µg/ml ampicillin containing-LB 
medium into a 500 ml glass bottle and cells were left to grow over night at 
37°C and 225 rpm. 
Bacterial cells were pelleted by a 30-minute centrifugation at 4,000 rpm at 
4°C and, after removal of LB medium, plasmid DNA wa s purified with the 
Qiagen Plasmid Maxi Kit (Qiagen) according to the manufacturer's 
instructions. 
Concentration and quality of the plasmid DNA were evaluated as described 
in the section 3. 
 
 
8. Bioinformatics analysis
 
 
We examined 14 cancer-related datasets with a total of 702 samples 
assayed on GPL5188 (Affymetrix Human Exon 1.0 ST) arrays for expression 
of survivin-∆Ex3 [Li,2005; Sampath & Pelus,2007]. Of the 14 datasets, 9 
compared cancer or cancer-related cells with normal controls, and 5 
compared either different cancers or the same cancer at different stages 
(Supplementary Table 1). The data were used as preprocessed and 
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normalized by the GEO contributors, and any technical replicates were 
averaged. 
The HuEx-1_0-st Affymetrix microarray platform contains 22 probesets 
designed to detect sequences derived from the three isoforms of the survivin 
locus (Figure 1A): NM_001168 (survivin), NM_001012270 (survivin-∆Ex3) 
and NM_001012271 (survivin-2B). Of the 22 probesets, 9 were retained in all 
14 datasets, and 13 were removed due to low expression (below 
background). Probesets 3 and 16 were also removed as their expression 
profiles were the same as 6 other probesets that targeted the same isoforms. 
Of the remaining probesets (Figure 1A), 8 of the 9 probes targeted regions 
that were common to all three survivin isoforms. Probeset 9 specifically 
targets exon 3, which is deleted in survivin-∆Ex3 [Li,2005; Sampath & 
Pelus,2007]. Specific expression of survivin-∆Ex3 was calculated as the 
difference between the average expression of the 8 common survivin 
probesets and probeset 9. 
 
 
9. Antibodies 
 
The following  antibodies to checkpoint kinase 2(Chk2, Santa Cruz, Santa 
Cruz, CA, USA), Thr68 phosphorylated Chk2 (Cell Signaling, Danvers, MA, 
USA), survivin (Novus Biologicals, Littleton, CO, USA),p53 (Calbiochem, 
Rockland, MA, USA), p53 and Ser15-phosphorylated p53 (Cell Signaling), 
p21 (Calbiochem), Ser139-phosphorylated histone H2AX (γH2AX; clone 
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JBW301, Millipore, Billerica, MA, USA), Alexa Fluor® 488 (cat. # A-11017, 
Invitrogen, Carlsbad, CA), FLAG (Sigma-Aldrich), β-actin (Sigma-Aldrich), 
COX IV (Cell Signaling), and RCC1 (Santa Cruz) were used. 
 
 
10. Mutagenesis
 
 
Mutagenesis of a 1.6 kb human survivin-∆Ex3 cDNA was carried out using 
QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the 
manufacture instructions. Ala substitutions of predicted Chk2 phosphorylation 
sites Thr79→Ala, Thr127→Ala, and Ser98→Ala in the unique –COOH 
terminus sequence of survivin-∆Ex3 was carried out with the following 
oligonucleotides (mutated sequences underlined):  
5’-ATGCAAAGGAAACCAGCAATAAGAAGAAAGAAT-3’ 
(Thr79,ACA→GCA),  
5’-TTATTCCCTGGTGCCGCCAGCCTTCCTGTGGGC-3’ 
(Thr127,ACC→GCC),  
5’-AATCCATGGCAGCCAGGCGCTCGATGGCACGGC-3’ 
(Ser98,AGC→GCC). 
Primers were purchased by IDT (Coralville, IA, USA). PCR products were 
then loaded on agarose gel (2%), the bands were excised and PCR products 
were purified with QIAquick® Gel Extraction Kit (QIAGEN) according to the 
manufactureʼs instructions.  
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Mutant constructs were confirmed by DNA sequencing, and inserted into 
pcDNA 3.0 or pGEX4T vectors, using EcoRI and XhoI restriction sites. 
 
 
11. Transfections 
 
Twenty-four hours prior to transfection, cell types were seeded in 2 ml of 
fresh media at a density of 2 x 106 cells in 6-well plates (Corning-Costar). 
Just prior to transfection, the medium was removed and the fresh PBS was 
gently added in order to wash the cells. In a 0.5 ml tube, 4 µg of various 
FLAG-tagged (DYKDDDDKC) cDNA constructs and Lipofectamine2000TM 
(Lipo 2000), (Invitrogen) were incubated with 250 µl Opti- MEM® I 
(Invitrogen) per well at room temperature for 10 minutes. After the incubation, 
the diluted plasmids were combined with the diluted Lipo2000 (total volume is 
500 µl) and incubated for 20 minutes. at room temperature to allow the 
plasmids:Lipo2000 complexes to form. This solution was then added to the 
cells and the plate was gently swirled to ensure uniform mixing. After 4 hours 
incubation at 37°C in a 5% CO 2 humidified atmosphere, the transfection 
cocktail was washed out and replaced with fresh medium.  
Gene silencing by small interfering RNA (siRNA) was carried out with 
control (VIII) or SMART pool siRNA oligonucleotides directed against Chk2 or 
survivin-∆Ex3 (Dharmacon), by oligofectamine (Invitrogen).  
The day before transfections, each cell line was seeded at a density of 2 x 
106 cells in 6-well plates (Corning-Costar). A given amount of each siRNA 
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was diluted in 200 µl of Opti-MEM® I reduced serum medium (Invitrogen) 
and incubated for 15 minutes. At the same time, the oligofectamine was 
diluted in 15 µl of Opti-MEM® I medium and incubated for 15 minutes at 
room temperature. After the incubation, the diluted siRNA was combined with 
the diluted oligofectamine (total volume is 200 µl) and incubated for 30 
minutes at room temperature to allow the siRNA:oligofectamine complexes to 
form. The mixtures were then applied to the cells in a final volume of Opti-
MEM® I medium giving a final siRNA concentration of 50 nM.  
After 4 hours incubation at 37°C in a 5% CO 2 humidified atmosphere, a 
solution 3X FBS medium was added to each well.  
 
 
12. Protein expression & purification
 
 
Recombinant GST fusion proteins were expressed in E. coli BL21-
CodonPlus-RIL (Stratagene, Wilmington, DE, USA) Recombinant GST-fusion 
proteins were induced in E.coli BL-21 strain with 0.3 mM IPTG for 3 hours at 
room temperature. After centrifugation cells were lysed with lysis buffer 
according to their solubility and the supernatant was directly used for binding 
to glutathione Sepharose 4B beads 50% slurry (Sigma). After overnight of 
binding, washes were performed in Hunt wash buffer (20 mM Tris-HCl pH8; 
100 mM NaCl; 1 mM EDTA; 0.5% NP-40; 100 µg/ml PMSF; 1 µg/ml 
leupeptin; 1 µg/ml aprotin) and in PBS 1X and GST Fusion Protein were 
purified with B-PER GST Fusion Protein Spin Purification Kit (Pierce, 
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Rockford, IL,USA). Protein concentrations of the different elution fractions 
were measured using a protein assay reagent (Bio-Rad) using BSA as 
standard and analyzed by SDS-PAGE. 
 
 
13. Protein analysis & turnover 
 
Tumor cell types (6-7x107) were fractionated in mitochondrial and cytosolic 
extracts using the ApoAlert Cell Fractionation Kit (BD Biosciences, Clontech, 
Mountain View, CA, USA), according to the supplier’s instructions. The 
isolated cytosolic fraction was further centrifuged at 10,000 g for 25 minutes 
at 4°C, and the supernatant was collected. Alternat ively, mitochondrial 
extracts were prepared from cell typers (5 × 107) washed in TD buffer (135 
mM NaCl, 5 mM KCl, 25 mM Tris-Cl, pH 7.6) and allowed to swell for 10 
minutes in ice-cold hypotonic CaRSB buffer (10 mM NaCl, 1.5 mM CaCl2, 10 
mM Tris-HCl, pH 7.5, plus protease inhibitors). Cells were Dounce-
homogenized with 70 strokes, with addition of MS buffer (210 mM mannitol, 
70 mM sucrose, 5 mM Tris, pH 7.6) to stabilize mitochondria (2 ml of 2.5× 
per 3 ml of homogenate). After removal of nuclear contaminants by 
centrifugation at 600 g for 15 minutes on ice, the supernatants were layered 
over a 1- to 2-M sucrose step gradient (10 mM Tris, 5 mM EDTA, pH 7.6, 2 
mM DTT, plus protease inhibitors) and centrifuged at 110,000 g for 30 
minutes at 4°C. Mitochondria were collected at the 1- to 1.5-M interphase by 
lateral suction through the tube, washed in 4 volumes of MS buffer at 9,400 
g, and suspended in a final volume of 200 µl of MS buffer. The top layer, 
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containing a cytosolic and a free protein fraction, was collected and used in 
parallel experiments. The purity of mitochondrial fractions was examined by 
immunoblotting with antibody to mitochondrial COX IV (Cell Signaling). 
Nuclear and cytosolic fractions were extracted using CelLytic NuCLEAR 
ExtractionKit (Sigma) according to the manufacture’s instructions. The purity 
of nuclear fractions was evaluated by immunoblotting with RCC1 antibody 
(Santa Cruz). 
Pull down experiments with recombinant fusion proteins (10 µg) were 
carried out. Total extracts from LN229 cells were incubated with IgG or an 
antibody to Chk2 or Hsp60 and the immune complexes were precipitated by 
the addition of protein A-Sepharose beads (Amersham) in 50 mm Tris, pH 
7.5, 0.1% deoxycholate, 1% Nonidet P-40, 0.1% SDS, 50 mm NaCl, 1 mm 
protease inhibitors (Roche Applied Science, Indianapolis, IN, USA), and 1 
mm Na3Vo4. After washing, pellets or supernatants were separated by SDS-
gel electrophoresis and analyzed by Western blotting. 
For protein stability, HCT116 cells at 60% confluency were transfected 
with cDNAs encoding control plasmid, WT survivin, survivin ∆Ex3 or 
survivin ∆Ex3 carrying Ala substitutions in the three Chk2 phosphorylation 
sites (survivin-∆Ex3-Mut3), by lipofectamine. After 24 h, transfected cells 
were treated with 0.1 mg/ml cycloheximide(Sigma), harvested after 0, 2, 4, 
and 6 h, and total cell extracts were analyzed by Western blotting. 
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14. Western Blot Analysis 
 
Equivalent amounts of cellular extracts fractionated, were blotted onto 
solid support and immunoassayed to qualitatively evaluate the expression of 
the proteins of interest. 
 
 
14.1. SDS-Polyacrylamide Gel Electrophoresis 
 
Samples were separated on 5% or 12% SDS polyacrylamide gels.  
An aliquot of cellular extracts containing 40 µg of proteins were mixed in a 
0.5 conical tube with an equal volume of 2x SDS loading buffer (100 mM 
Tris-HCl pH 6.8, 4% (w/v) SDS, 0.2% (w/v) bromophenol blue (Sigma), 20 
(v/v) glycerol and 200 mM DTT). Tubes were heated at 100°C for 5 minutes, 
chilled on ice for an additional 5 minutes, centrifuged at 4°C at 12,000 rpm 
for 5 seconds and loaded onto the SDS-PAGE system. 
Proteins were fractionated running the gel at constant voltage (150 volt) by 
means of a Biorad 200/2.0 power supply (Biorad). The run was stopped 
when the 6.8 KDa band of the colour marker reached the bottom of the gel. 
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14.2. Transfer of Fractionated Proteins into Nitrocellulose Filter 
 
Protein blotting was performed in an electrophoresis protein transfer unit 
(Biorad). When the SDS-PAGE was approaching the end of its run, one 
piece of Immobilon-PSQ membranes (Millipore) was cut and soaked in 
Methanol (Fisher Scientific). After 1 minute the membrane and four pieces of 
Whatman 3MM (Whatman International LtD., Maidstone, United Kingdom) 
and), were soaked for at least 5 minutes in transfer buffer [50 mM Tris base, 
100 mM Glycine, 0.01% (w/v) SDS, 20% (v/v) methanol (Fisher Scientific), 
pH 7.5]. At the end of the run, the glass plates holding the SDS-
polyacrylamide gel were removed from the electrophoresis tank, the glass 
plates were opened and, by means of a scalpel, the stacking gel was 
removed. The resolving gel was placed exactly on the top of the filter and 
then sandwiched between two pairs of transfer buffer wetted-Whatman 3MM 
papers. Possible air bubbles trapped were displaced by repeated rolling with 
a pipette tip. The sandwich was then placed between two transfer buffer 
wetted-porous pads and two plastic supports and the entire construction was 
immersed in the electrophoresis transfer tank containing transfer buffer with 
the filter placed toward the anode. Transfer of the protein from the gel to 
nitrocellulose membrane was carried out on ice for 1 hours at 0.35 amper 
(constant amperage) by means of a Biorad 200/2.0 power supply. 
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14.3. Immunological Detection of PVDF-Immobilised Proteins 
 
At the end of the transfer, the PVDF filter was recovered from the 
sandwich and, in order to verify the correct protein blotting, it was stained for 
5 minutes in a clean tray containing a Ponceau S red dye solution (Sigma) 
with gentle agitation at room temperature. When the bands of proteins were 
visible, the filter was destained with several washes of distilled water at room 
temperature. To completely destain the Ponceau S red dye bound to the 
proteins, nitrocellulose slices were washed three times for 20 minutes at 
room temperature on a shaking platform with blocking solution [5% (w/v) 
dried-nonfat milk, 0.1% (v/v) Tween-20 (Sigma) and PBS]; filter slices were 
then incubated at room temperature on a shaking platform in blocking 
solution to mask potential nonspecific antibodies binding sites and, thus, to 
reduce general background. After 1 hour, blocking solution was removed and 
filters were incubated over night at 4°C on a shaki ng platform with the 
specific antibody-containing solution. Detection of proteins of interest was 
achieved by using polyclonal or monoclonal antibodies diluted in blocking 
solution. At the end of the over night incubation, primary antibodies were 
removed and filter slices were washed 3 times for 20 minutes with T-PBS 
wash solution [0.1% (v/v) Tween-20 in PBS] at room temperature on a 
shaking platform. PVDF filters were then incubated at room temperature on a 
shaking platform with the secondary anti-mouse or anti-rabbit Ig horseradish 
peroxidase-linked whole antibodies (Amersham) diluted 1:1000 in blocking 
solution. After a 1-hour hybridisation, secondary antibodies were removed 
and filter slices were washed three times for 20 minutes at room temperature 
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on a shaking platform with T-PBS wash solution followed by a rapid wash 
with PBS. Antibodies bound to proteins of interest on PVDF slices were 
detected by means of the enhanced chemoluminescence system (ECL) 
(Amersham) according to the manufacturer's instructions using Kodak Bio 
Max Film (Kodak, Sigma). 
 
 
15. Kinase assays
 
 
Recombinant proteins were incubated with human active Chk2 (R&D 
Systems, 0.1 µg/µl) in kinase buffer (pH 7.2) containing 25 mM MOPS, 12.5 
mM β-glycerolphosphate, 25 mM MgCl2, 5 mM EGTA, 2 mM EDTA, 0.25 mM 
DTT, and 0.1 mM ATP in the presence or absence of 32P-γATP (Amersham) 
for 20 min at 30°C. Recombinant Cdc25 was used as a  control Chk2 
substrate. In control experiments, Chk2 was omitted from the kinase reaction. 
At the end of the incubation, the various samples were separated by SDS gel 
electrophoresis, and phosphorylated bands were detected by 
autoradiography. Equal protein loading under the various conditions was 
confirmed by Coomassie blue staining of the gel. 
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16. Flow cytometry analysis
 
 
Tumor cell types were treated with vehicle or the DNA-damaging agent 
etoposide (2.5 µM) or camptothecin (CPT, 2.5 µM) for 16 h at 37°C, fixed in 
70% ethanol for 30 min and then incubated for 16 h with a solution of 
propidium iodide (PI) in PBS, pH 7.4. 
Cells were analyzed for DNA content by flow cytometry with collection of 
10,000 events per sample, and analysis using FlowJo software (Tree Star, 
Ashland, OR, USA). For detection of γH2AX, HCT116 cells were transfected 
with control vector, WT survivin, survivin-∆Ex3 or Chk2 phosphorylation-
defective survivin-∆Ex3-Mut3, treated with etoposide or CPT (1.25-2.5 µM) 
for 12 h, and fixed in 1% paraformaldehyde for 15 min and 70% ethanol for 
30 min. After permeabilization with a solution of 0.2% Triton X-100 plus 1% 
BSA in PBS, pH 7.4 for 10 min, cells (1x106) were incubated with a primary 
antibody to γH2AX for 90 min followed by Alexa Fluor® 488 secondary 
antibody for additional 60 min. Cells were washed, stained with PI and 
analyzed by multiparametric flow cytometry. Ten thousand events were 
collected and analyzed using FlowJo software. Data on y-axis represent the 
levels of γH2AX expressed as arbitrary fluorescence units. 
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17. Homologous double strand DNA break reapir assay
 
 
A pDR-GFP plasmid that utilizes two modified GFP genes (I-Sce1-GFP 
and iGFP) to create a recombination reporter was used. Transfection of the I-
Sce1 endonuclease in cells stably expressing pDR-GFP results in DSB at the 
position of the I-Sce1 site, whose repair by a non-crossover gene conversion 
with iGFP reconstitutes a functional GFP gene. Cells were analyzed by flow 
cytometry on a green (FL1) versus orange (FL2) fluorescence plot with 20% 
or 25% orange minus green compensation to aid in the detection of faint 
positives. GFP-negative cells possess autofluorescence and fall along the 
green/orange diagonal, whereas GFP+ cells appear in a separate population 
shifted off the diagonal of cells and toward FL1. Stable clones of HCT116-
pDR-GFP cells were transfected with pCMV-I-SceI alone or together with WT 
survivin, survivin-∆Ex3 or survivin ∆Ex3-Mut3 cDNA. After 3 d, cells (2-5x104) 
were trypsinized, suspended in PBS, pH 7.4, containing 0.5% FBS, and 
analyzed by multiparametric flow cytometry with quantification of the 
percentage of green fluorescent cells relative to the total cell number. 
 
 
18. Soft agar colony formation
 
 
HCT116 cells (5x105) were transfected with pcDNA, survivin-∆Ex3 or 
survivin-∆Ex3-Mut3, treated with or without etoposide (1.25 µM), and 
suspended in 1.5 ml of DMEM supplemented with 10% FBS and 0.35% 
bactoagar (Becton Dickinson, Sparks, MD) in 36 mm tissue culture plates 
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containing 1.5 ml of 0.75% agarose in growth medium at the bottom layer. 
Plates were incubated at 37°C in a 5% CO2 incubator for 2 weeks. Colonies 
were stained with 0.005% crystal violet (Sigma), visualized by phase 
contrast microscopy, and counted using a dissecting microscope under high-
power field. The size of colonies (≤100 µm or 100-200 µm) was quantified 
using NIH Image J software. 
Experiments were repeated twice with similar results. 
 
 
19. Histology
 
 
Primary human tissue samples devoid of all patient identifiers were 
obtained anonymously after informed consent from the Department of 
General and Gastroenterological Surgery at Osaka Medical College. 
Specimens were obtained from patients undergoing surgical or endoscopic 
resections, and were representative of different stages of the adenoma-
tocarcinoma transition of the colonic epithelium. A histologic diagnosis of 
normal colon, hyperplasia, moderate or severe dysplasia, or adenocarcinoma 
was obtained for each sample by independent pathological review of 
hematoxylin-eosin (H&E)-stained tissue slides. Samples were processed for 
antigen retrieval, as described (20), and analyzed for expression of survivin, 
Chk2, Thr68-phosphorylated Chk2 or p53, by immunohistochemistry. Twenty 
cases per each condition were scored, and a cutoff of 5% positively stained 
cells was used. 
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20. Statistical analysis 
Data were analyzed using the unpaired t test on a GraphPad software 
package for Windows (Prism 4.0). All tests on gene expression analysis of 
survivin-∆Ex3 were done using samples for each GEO dataset separately. 
Differences in survivin-∆Ex3 gene expression in datasets with paired 
cancer/control samples (datasets 3 and 4) were tested using the two-tail t-
test. Additional comparisons were done to estimate the significance of 
association of survivin-∆Ex3 expression with available annotation data using 
the Spearman correlation test. The level of significance was set at p<0.05 
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1. DIFFERENTIAL EXPRESSION OF SURVIVIN-∆EX3 IN HUMAN 
CANCER 
 
We began this study by taking an unbiased bioinformatics approach to 
examine the expression of survivin-∆Ex3 in 14 publicly available cancer-
associated GEO datasets with gene expression profiles assayed by 
Affymetrix human exon arrays (Table II). A schematic diagram of the 
genomic organization of the survivin gene, and its relationship to the 
probesets on the arrays are shown in Figure 17A. By principal component 
analysis (Figure 18A), the expression of probeset 9 (deleted in survivin-∆Ex3) 
across samples differed from that of other 8 probesets common to all the 
survivin isoforms, demonstrating the ability of the microarray platform to 
distinguish between survivin isoforms that either contain or lack exon 3 
(Figure 18A). A hierarchical clustering based on differential probeset 
expression patterns is shown in Figure 18B. Given the average expression of 
probesets 4, 5, 13, 14, 15 and 17 (X = cumulative expression of all three 
isoforms) and probeset 9 (Y = expression of survivin and survivin-2B isoform, 
but not survivin-∆Ex3), we determine that Y<X for the majority of samples, 
indicating an expected relation between exon expression (Figure 17B). The 
specific expression of survivin-∆Ex3 was then calculated as the difference X-
Y, and then log2 transformed for further investigation. By this analysis, 
survivin-∆Ex3 mRNA was found to be expressed at significantly higher levels 
in tumors of the ovary, stomach, brain, lung and prostate, as compared to 
matched normal tissues (Figure 17C). When analyzed for a potential 
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relationship with disease progression, survivin-∆Ex3 levels were elevated in 
grade IV glioblastoma compared to low grade oligodendrogliomas, in 
metastatic compared to localized prostate cancer, and in stage 4 compared 
to stage 1 neuroblastoma (Figure 17D and Table III). Consistent with these 
findings, increased expression of survivin-∆Ex3 also correlated with poorer 
survival (p=0.01, spearman correlation), greater incidence of recurrence 
(p=6x10-5, spearman correlation) and advanced Gleason grade (p=0.0004) 
in prostate cancer, N-myc amplification in neuroblastoma, H.pylori infection in 
gastric cancer, and chromosome 11q13 amplification in squamous head and 
neck cancer (Table III). 
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Table II. GEO mRNA datasets used in the study 
 
#        GEO                             Study Set                                        
        acc 
Tot     Control     Cancer 
1 
 
 
 
    2 
 
 
    3 
 
 
 
    4 
 
    5 
 
 
 
 
    6 
 
 
    7 
 
 
    8 
 
 
    9 
 
 
 
   10 
 
 
   11 
 
 
 
12 
 
 
13 
 
 
 
 
14 
   GSE 9385     Identification of differentially  
                         regulated splice variants and  
                         novel exons in glial   brain tumor  
                         using exon arrays  (PMID: 17575129) 
   GSE 11967   Identifying alternative hyper-splicing               
                      signatures in MG-thymoma by exon   
                      arrays (PMID: 18545673) 
GSE 12236   Whole Genome Exon Arrays Identify     
                         differential Expression of Alternatively  
                         Spliced, Cancer-related Genes in Lung  
                         Cancer (PMID: 18927117) 
 GSE 13195    Gene expression and alternative   
                          splicing in human gastric cancer 
   GSE 21034    Whole-transcript and exon-level  
                          expression data for human primary and  
                          metastatic prostate cancer samples and 
                          control normal adjacent benign prostate 
                        (PMID: 20579941)   
   GSE 21440    Gene expression analysis of pancreatic 
                          cancer associated fibroblasts  
                          (PMID: 20215540) 
 GSE 23361    Significant Downregulation of Platelet  
                          Gene Expression in Metastatic Lung  
                          Cancer (PMID: 21500395) 
   GSE 29156    Serous ovarian benign tumor and type II 
                          carcinoma data set for expression and 
                          paracrine signaling investigation 
   GSE 29301    Exon-Level Expression Data from 
                      Primary Human B Cells and     
                      Lymphoblastoid Cell Lines (LCLs) on  
                      HuEx and U133 2.0 plus Platforms 
 GSE 16534    Exon array profiling detects EML4-ALK 
                         fusion in breast, colorectal and non-small 
                         cell lung cancers. (PMID: 19737969) 
  GSE 27388    Exon-array profiling of squamous cell  
                      carcinoma and adenocarcinoma in  
                      human cervical FFPE samples 
                      (PMID:21407225) 
   GSE 27501   Quantitative Analysis of Alternative  
                         Spliced Variants in HNSCC  
                         (PMID: 21745820) 
   GSE 27608   Exon array analysis reveals    
                         neuroblastoma tumors have distinct  
                         alternative splicing patterns according to 
                         stage and MYCN amplification status 
                         (PMID: 21501490)  
GSE 29682   Comparison between cell lines from 9  
                     different cancer tissue (NCI-60)  
 
       55           6               49 
  
 
 
     4            2                2 
 
 
       40          20              20 
  
 
 
       50          25              25 
 
      179         29             150 
  
 
 
 
       12           3                9 
 
 
       12           7                5 
 
 
       39          31               8 
 
 
        8            4                4 
 
 
 
     153          na             153 
 
 
       28          na               28 
 
 
 
       15          na               15 
 
 
       47          na               47 
 
 
 
 
       60          na              60 
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Figure 17A-B. Genome-wide bioinformatics analysis of survivin-∆Ex3 
expression in cancer. 
A. Schematic diagram of genomic organization of WT survivin, spliced variants 
survivin-2B and -∆Ex3 (top), and distribution of probesets and datasets with 
significant expression (bottom).  
B. Ratio between probeset 9 targeting NM_001168 (WT survivin) and 
NM_001012271 (survivin-2B), and average expression of probesets targeting all 
surviving  isoforms (expected ratio is <1). The different colors indicate samples 
from 14 different datasets, incremental from the 1st dataset on the left to the 14th 
dataset on the right.  
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Figure 17C-D. Genome-wide bioinformatics analysis of survivin-∆Ex3 
expression in cancer. 
C. Fold upregulation of survivin-∆Ex3 expression in the indicated tumor types 
relative to matched normal tissues within each dataset. The number of cases in the 
normal (N) or tumor (T) group is as follows: ovary (N, n=31; T, n=8); stomach (N, 
n=25; T, n=25); brain (N, n=6; T, n=49); lung (N, n=20; T, n=20); prostate (N, n=29; 
T, n=150); thymus (N, n=2; T, n=2). Mean±SEM.  
D. Increased expression of survivin-∆Ex3 during tumor progression. OD, 
oligodendroglioma; GBM, grade IV glioblastoma; PrCa, prostate cancer; NB, 
neuroblastoma. The number of cases per each condition is as follows: OD, n=2; 
GBM, n=28; localized PrCa, n=131; metastatic PrCa, n=19; stage (S) 1 NB, n=10; 
stage (S) 4 NB, n=37. For panels C and D, the dataset examined per each condition 
is indicated. Mean±SEM. 
 
 
 
 
 
 
 
Figure 18. GPL5188 platform probeset .  
A. Relationship between all probeset expression profiles.  
B. Hierarchical clustering of expression profiles of probesets retained for analysis. 
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Table III. Tissue expreession of survivin-∆Ex3. 
  
 Set   Cancer           Comparison(group1/group2)                     
         
n1      n2         Test              P             Value 
1 
 
    4 
 
    5 
 
    5 
 
    5 
 
    5 
 
    5 
 
  12 
 
  13 
 
  14 
Brain      glioblastoma / low grade oligodendroglioma 
      
   Gastric             Helicobacter pylori test yes/no    
    
   Prostate                 Metastatic/primary     
        
   Prostate           Death from prostate cancer   
                           
   Prostate         Biochemical recurrence (BCR)  
                           
   Prostate                 Pathological stage 
        
   Prostate                    Gleason grade 
        
   HNSCC            11q13 amplification yes/no 
                           
       NB               MYCN amplification yes/no 
                       
Renal                    Ploidy of the cell line 
   
    28        2         t-test           0.004         fc=3.42 
  
    14        9         t-test           0.005         fc=1.86 
 
    19      131       t-test           9x10-12          fc=1.42 
  
   140                spearman     0.01          rho=0.21 
 
   140                spearman     6x10-5       rho=0.33 
  
   141               spearman     0.02           rho=0.19 
 
   149               spearman     0.0004       rho=0.29 
 
     8         7        t-test           0.04            fc=1.81 
     
     9        38       t-test           0.02            fc=1.75 
 
     8                 spearman     0.005         rho=0.88  
 
HNSCC= HEAD AND NECK SQUAMOUS CELL CARCINOMA, NB=NEUROBLASTOMA, N 1=NUMBER 
OF SAMPLES IN GROUP 1, N 2=NUMBER OF SAMPLES IN GROUP 2, FC=UPREGULATION FOLD, 
RHO=SPEARMAN CORRELATION COEFFICIENT. 
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2. SUBCELLULAR LOCALIZATION OF SURVIVIN-∆EX3 
 
Transfection of FLAG-tagged survivin-∆Ex3 resulted in an exclusively 
nuclear localization in disparate tumor types, including HCT116, H460 or 
MDA-MB-431 cells (Figure 19A). In contrast, WT survivin was ubiquitously 
distributed in nuclear and cytosolic compartments in tumor cells [Fortugno et 
al., 2002]. In addition, survivin-∆Ex3 was excluded from mitochondria of 
transfected MDA-MB-431 or H460 cells (Figure 19B). 
Accordingly, treatment of H460 cells with a cell death stimulus, 
staurosporine (STS) caused loss of mitochondrial transmembrane potential, 
in a response unaffected by transfection of control plasmid or survivin-∆Ex3 
(Figure 20). 
To begin probing the function of survivin-∆Ex3 in tumor cells, we next 
designed  isoform-specific siRNA oligonucleotides that selectively ablate the 
expression of endogenous survivin-∆Ex3 in tumor cells. Transfection of MCF-
7 cells that constitutively express WT survivin [Dohi et al., 2007] with control, 
non-targeting siRNA did not significantly affect endogenous mRNA 
expression of survivin or survivin-∆Ex3, by RT-PCR (Figure 21, top). 
Conversely, transfection of isoform-specific siRNA reduced the expression of 
survivin-∆Ex3, whereas the levels of WT survivin were not affected (Figure 
21, bottom). Under these conditions, siRNA silencing of surviving or survivin-
∆Ex3 produced comparable defects in cell cycle progression, characterized 
by arrest at G2/M, and appearance of a cell population with >4N DNA 
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content, indicative of DNA endoreduplication (Figure 21, bottom) (Beltrami et 
al., 2004).  
 
 
 
 
 
Figure 19. Nuclear localization of survivin-∆Ex3 in cancer. 
A. The indicated tumor cell types were transfected with vector (pcDNA), FLAG-survivin 
(SVV) or FLAG-survivin-∆Ex3 cDNA, and isolated cytosolic (C) or nuclear (N) fractions 
were analyzed with an antibody to FLAG by Western blotting. RCC1 was used as a 
nuclear marker.  
B. The indicated tumor cell types were transfected as in A, and isolated cytosolic (C) or 
mitochondrial (M) fractions were analyzed with an antibody to FLAG by Western 
blotting. COX-IV was used as a mitochondrial marker. 
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Figure 20.  Mitochondrial transmembrane potential changes. 
MDA-431 cells were transfected with vector (pcDNA) or survivin-
∆Ex3 cDNA, treated with staurosporine (STS), and analyzed for 
changes in mitochondrial membrane potential by JC-1 staining and 
multiparametric flow cytometry. The data are expressed as ratio 
between green (FL1)/red (FL2) fluorescence. In each quadrant is 
indicated the percentage of cells. 
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Figure 21. RT-PCR and DNA content after siRNA transfection. 
MCF-7cells stably transfected with survivin were left untreated (None) or 
transfected with control (Ctrl) non-targeting or survivin- ∆Ex3-directed 
siRNA and analyzed by RT-PCR (top) or DNA content by propidium 
iodide (PI) staining and flow cytometry (bottom). The percentage of cells 
in the G2/M or >G2/M fraction is indicated. 
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3. CHK2 PHOSPHORYLATION OF SURVIVIN-∆EX3 
 
By sequence analysis, three potential phosphorylation sites matching the 
consensus for the DNA damage checkpoint kinase, Chk2 (Reinhardt & Yaffe, 
2009) were identified at Thr79, Ser98 and Thr127 in the unique -COOH 
terminus sequence of survivin-∆Ex3 (Figure 22A) (Li, 2005, Sampath & 
Pelus, 2007). In contrast, no putative Chk2 phosphorylation sites were 
identified in WT survivin. Consistent with these predictions, purified, active 
Chk2 readily phosphorylated recombinant survivin-∆Ex3 in a kinase assay, 
whereas WT survivin was not phosphorylated by Chk2 (Figure 22B). As 
control, Chk2 also phosphorylated its known substrate, Cdc25 (Figure 22B). 
Ala substitution of Thr127 in survivin-∆Ex3 (∆Ex3-Mut1), or double mutation 
of Thr79 and Ser98 (∆Ex3-Mut2) partially reduced phosphorylation by Chk2 
(Figure 22A). Conversely, Ala mutagenesis of all three putative 
phosphorylation sites in survivin-∆Ex3, including Thr127/Thr79/Ser98 (∆Ex3-
Mut3) abolished Chk2 phosphorylation in a kinase assay (Figure 22B). 
A potential regulation of survivin-∆Ex3 by Chk2 phosphorylation was next 
investigated. When expressed in HCT116 cells, survivin-∆Ex3 exhibited 
considerably accelerated protein degradation compared to WT survivin, with 
an estimated half-life of  2h, as opposed to 6h for the main survivin isoform, 
by clycloheximide block and release experiments (Figure 23). In contrast, a 
Chk2 phosphorylation-defective survivin-∆Ex3 mutant (survivin-∆Ex3-Mut3) 
was considerably more stable in HCT116 transfectants, with an approximate 
half-life of 4h (Figure 23). In these experiments, expression of survivin-∆Ex3 
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or survivin-∆Ex3-Mut3 did not significantly affect total Chk2 levels in 
transfected HCT116 cells (Figure 23). Consistent with a rapid turnover of 
survivin-∆Ex3 in tumor cells, pellets of LN229 cell extracts precipitated with 
recombinant GST-survivin or GST-survivin-∆Ex3 did not contain co-
associated Chk2, by pull down experiments and Western blotting (Figure 24, 
top). Conversely, recombinant survivin, but not survivin-∆Ex3 associated with 
the mitochondrial chaperone, Hsp60 (Figure 24, bottom), in agreement with 
previous observations (Ghosh et al., 2008).  
 
 
Figure 22. Chk2 phosphorylation of survivin-∆Ex3. 
A. Indication of the position of three putative consensus phosphorylation sites for 
Chk2 at Thr79, Ser98 and Thr127 in the unique -COOH terminus sequence of 
survivin-∆Ex3. B. Recombinant active Chk2 was incubated with recombinant 
survivin (SVV), survivin-∆Ex3 or survivin-∆Ex3 Thr127→Ala (Mut1), 
Thr79/Ser98→Ala (Mut2) or Thr127/Thr79/Ser98→Ala (Mut3) in a kinase assay, 
and radioactive bands were visualized by autoradiography. Recombinant Cdc25 
was used as a control for a Chk2 substrate. Bottom, Coomassie blue staining of 
recombinant proteins used inthe kinase assay. 
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Figure 23. Survivin expression and stability after cycloheximide treatment. 
HCT116 cells were transfected with the indicated plasmids, treated with 
cycloheximide, harvested at the indicated time intervals after release and 
analyzed by Western blotting.  
Bottom, densitometric quantification of protein bands. Similar results were 
obtained in an independent experiment: survivin-∆Ex3, 2 h, 61.2%; 4 h, 
40.6%; 6 h, 3.6%; survivin-∆Ex3-Mut3, 2 h 58.1%; 4 h, 48.7; 6 h, 25.7%. 
 
 
 
 
Figure 24. Pull down experiments and Western Blotting. 
Recombinant GST, GST-survivin (SVV) or GST, survivin-∆Ex3 were 
incubated with LN229 total cell extracts (TCE) and bound proteins 
were analyzed with an antibody to Chk2 (top) or Hsp60 (bottom) by 
Western blotting. Recombinant proteins used for the pull down 
experiments were stained with Coomassie blue (bottom panels) 
.  
FLAG
Chk2
β-actin
∆ex3 ∆ex3-Mut3SVVVector
0  2  4  6 0  2  4  6
Time (h)
0  2  4  6 0  2  4  6
Time (h)
Coomassie
Coomassie
Chk2
Hsp60
 
 135 
4. PARTICIPATION OF SURVIVIN-∆EX3 IN A DNA DAMAGE-SENSING 
CHECKPOINT IN TUMOR CELLS 
 
Based on these results, we next asked whether survivin-∆Ex3 contributed 
to Chk2 regulation of the DNA damage response (Jeggo & Lobrich, 2007), 
and we treated HCT116 cells with the topoisomerase II inhibitor and inducer 
of double strand DNA breaks (DSB), etoposide. DNA damage induction 
under these conditions resulted in the appearance of Ser139-phosphorylated 
histone H2AX, or γH2AX (Bonner et al., 2008), a marker of unrepaired DNA 
damage (Jeggo & Lobrich, 2007), in a reaction that peaked 16 h after 
treatment (Figure 25A,B). Transfection of HCT116 cells with WT survivin or 
survivin-∆Ex3 did not affect the kinetics or magnitude of γH2AX reactivity 
after etoposide treatment (Figure 25A,B). In contrast, expression of Chk2 
phosphorylation-defective survivin-∆Ex3-Mut3 abolished γH2AX reactivity in 
response to etoposide (Figure 25A,B). 
To test the specificity of γH2AX reactivity by survivin-∆Ex3, we next treated 
HCT116 cells with the topoisomerase I inhibitor, camptothecin (CPT), which 
induces single strand DNA breaks. CPT induced robust and time-dependent  
γH2AX reactivity in HCT116 cells transfected with control vector (Figure 
25C). Differently from the results obtained with etoposide, transfection of 
HCT116 cells with WT survivin, survivin-∆Ex3 or survivin-∆Ex3-Mut3 did not 
reduce γH2AX reactivity in response to CPT treatment (Figure 25C). 
Second, we asked whether Chk2 phosphorylation of survivin-∆Ex3 
affected homologousdirected DSB repair. For these experiments, we used 
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HCT116 cells stably transfected with two modified GFP genes that create a 
GFP-DR recombination reporter (Pierce et al.,1999, Moynahan et al., 2001). 
Co-transfection of HCT-pDR-GFP cells with pCMV-I-SceI and control vector 
caused the appearance of GFP+ cells indicative of homologous DSB repair 
(Figure 26) (Pierce et al.,1999, Moynahan et al., 2001). Co-transfection of 
WT survivin, survivin-∆Ex3 or survivin-∆Ex3-Mut3 cDNA together with pCMV-
I-SceI did not significantly affect homologous DSB repair (Figure 26). As 
control, no GFP+ cells were detected in the absence of pCMV-I-SceI (Figure 
26), confirming that spontaneous intrachromosomal DNA conversion was 
negligible with this assay (Pierce et al.,1999, Moynahan et al., 2001).  
 
 
Figure 25. Survivin-∆Ex3 regulation of a DNA damage sensing checkpoint.  
A. HCT116 cells were transfected with vector (pcDNA), survivin (SVV), survivin-∆Ex3 or 
Chk2 phosphorylation-defective survivin-∆Ex3-Mut3 cDNA, treated with etoposide and 
analyzed after 16 h for γH2AX (y-axis) and PI (x-axis) staining by multiparametric flow 
cytometry. B. The experimental conditions are as in A, except that expression of γH2AX in 
transfected HCT116 cells was normalized at the indicated time intervals after etoposide 
treatment. C. HCT116 cells were transfected as in A, treated with camptothecin (CPT), and 
analyzed for γH2AX expression at the indicated time intervals. In the panels B and C are 
shown two independent experiments (Expt). 
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Figure 26. Homologous directed DSB repair. 
HCT116 DR-GFP cells were transfected with pCMV-I-SceI without (None) or with pcDNA, 
survivin (SVV), survivin-∆Ex3 or survivin-∆Ex3-Mut3 cDNA, and analyzed for changes in GFP 
expression, by multiparametric flow cytometry. The percentage of GFP+ cells under the 
various conditions tested is indicated. PE, phycoerythrin. 
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5. REQUIREMENTS OF SURVIVIN-∆EX3 FOR A DNA DAMAGE-SENSING 
CHECKPOINT  
 
A key regulator of the DNA damage-sensing pathway is the Mre11-Rad50-
Nsb1 (MRN) complex (Takemura et al., 2006), and its potential participation 
in modulation of γH2AX reactivity by survivin-∆Ex3 was next investigated. 
Transfection of survivin-∆Ex3 in colorectal adenocarcinoma SW480 cells, 
which contain normal levels of the MRN complex, as opposed to HCT116 
cells (Takemura et al., 2006), resulted in robust γH2AX expression in 
response to etoposide, by Western blotting (Figure 27A). In contrast, 
expression of survivin-∆Ex3-Mut3 nearly completely abolished γH2AX 
reactivity after DNA damage (Figure 27A). 
We next asked whether Chk2 phosphorylation of survivin-∆Ex3 affected 
downstream pathway(s) of the DNA damage response. Similar to the data 
above, transfection of survivin-∆Ex3-Mut3 suppressed time-dependent 
γH2AX induction in etoposide-treated HCT116 cells, by Western blotting 
(Figure 27B). In contrast, etoposide-induced Ser15 phosphorylation of p53, 
increased levels of total p53 levels, or upregulation of the cyclin dependent 
kinase inhibitor, p21, were indistinguishable in HCT116 cells expressing 
survivin-∆Ex3 or survivin-∆Ex3-Mut3 (Figure 27B). Also, no differences were 
observed in the kinetics of etoposide-induced Chk2 phosphorylation on Thr68 
in the presence of survivin-∆Ex3 or survivin-∆Ex3-Mut3 (Figure 27B). 
We next asked whether defective γH2AX expression by survivin-∆Ex3-
Mut3 affected clonogenic tumor cell survival. In the absence of etoposide, 
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transfection of HCT116 cells with survivin-∆Ex3 or survivin-∆Ex3-Mut3 
significantly enhanced colony formation in soft agar, compared to control 
transfectants (Figure 28), suggesting a cytoprotective role of both molecules 
irrespective of DNA damage or Chk2 phosphorylation. After etoposide-
induced DNA damage, expression of survivin-∆Ex3 still supported HCT116 
colony formation (Figure 28). In contrast, transfection of survivin-∆Ex3-Mut3 
preferentially impaired the ability of HCT116 cells to form larger colonies of 
up to 200 µm diameter after etoposide treatment (Figure 28). 
 
 
Figure 27. Requirements of survivin-∆Ex3 during the DNA damage response. 
A.SW480 cells were transfected with survivin-∆Ex3 or Chk2 phosphorylation-defective 
survivin-∆Ex3-Mut3 cDNA, treated with etoposide and analyzed after the indicated time 
intervals, by Western blotting.  
B. HCT116 cells were transfected with survivin-∆Ex3 or survivin-∆Ex3-Mut3 cDNA, treated 
with etoposide and analyzed at the indicated time intervals by Western blotting. 
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Figure 28. Clonogenic tumor cell survival. 
HCT116 cells were transfected with vector (pcDNA), survivin-∆Ex3 or 
survivin-∆Ex3 cDNA, left untreated (None) or exposed to etoposide, and 
analyzed for colony formation in semisolid medium after 10 day. Colonies 
were imaged by phase contrast microscopy (magnification, x50), and 
quantified for diameters of 50-100 υm or 100-200 υm using Image J 
software. Mean±SEM of replicates from two independent experiments. 
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6. EXPRESSION OF ACTIVE CHK2 DURING STEPWISE 
TUMORIGENESIS IN HUMANS 
 
Analysis of human tissue samples representative of the colorectal 
adenoma-to-carcinoma transition revealed that Thr68-phosphorylated Chk2 
was abundantly expressed at the earliest changes of colonic hyperplasia, 
and throughout all stages of colorectal tumorigenesis, including moderate or 
severe dysplasia and adenocarcinoma (Figure 29A, B). In contrast, Thr68-
phosphorylated Chk2 was undetectable in the normal colonic epithelium, and 
total Chk2 protein levels were comparable at all stages of colorectal 
tumorigenesis, as well as in the normal mucosa of the colon (Figure 29A, B). 
In addition, reactivity for survivin and p53 began to increase in dysplastic 
lesions of the colon, and their expression remained elevated in colorectal 
adenocarcinomas (Figure 29A, B).  
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Figure 29. Chk2 activation during colorectal tumorigenesis, in vivo. 
A. Patient-derived surgical or endoscopic specimens representative of 
progressive stages of the colorectal adenoma-to-carcinoma transition 
(normal mucosa, hyperplasia, moderate dysplasia, severe dysplasia 
and adenocarcinoma) were analyzed for expression of Thr68-
phosphorylated Chk2, survivin, p53, or Chk2, by immunohistochemistry.  
B. Tissue slides representative of the indicated histologic diagnoses (20 
cases/each) were scored for positively stained cells using a 5% cutoff. 
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In this study, we have shown that survivin-∆Ex3, a survivin spliced variant 
with still largely elusive functions (Li, 2005, Sampath & Pelus, 2007), is a 
nuclear protein phosphorylated by the DNA damage checkpoint kinase, Chk2 
(Reinhardt & Yaffe, 2009) on three novel amino acids located in its unique –
COOH terminus region. Expression of non-phosphorylatable survivin-∆Ex3 
exhibited enhanced stability in vivo, suppressed γH2AX reactivity specifically 
in response to DSB, and impaired long-term clonogenic tumor cell survival. 
When analyzed in human tumors, survivin-∆Ex3 was differentially expressed 
in the transformed cell population, correlating with advanced disease and 
other markers of unfavorable prognosis. 
A potential involvement of the survivin pathway in the DNA damage 
response has emerged in recent studies. Although this was originally linked 
to the ability of survivinexpressing cells to counter radiation-induced 
apoptosis (Kanwar et al., 2010), recent evidence suggested a more direct 
role for survivin in specific aspects of DNA damage and repair mechanisms, 
potentially independent of cytoprotection (Rodel et al., 2011). Accordingly, 
siRNA or dominant negative targeting of survivin was associated with 
reduced DNA repair response(s), especially in gliomas (Chakravarti et al., 
2004), and exposure of tumor cells to YM155, a small molecule survivin 
inhibitor currently in the clinic (Giaccone et al., 2009), delayed repair of DSB 
(Iwasa et al., 2008). The molecular basis of these responses has not been 
clearly elucidated, but initial evidence suggested a potential role of survivin in 
controlling the expression of the DNA repair protein, Ku70 (Jiang et al., 
2009). 
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The data presented here extend these observations, and anticipate a role 
of the surviving spliced variant, ∆Ex-3 (Li, 2005, Sampath & Pelus, 2007) in 
sensing the presence of unrepaired DNA damage in tumor cells. 
This is a novel role for a molecule whose subcellular localization and 
function(s) have remained largely controversial in the literature, with reports 
variously implicating survivin-∆Ex-3 in nucleolar-dependent apoptosis 
inhibition (Song & Wu, 2005), mitochondrial control of Bcl-2 and caspase 3 
activation (Wang et al., 2002, Malcles et al., 2007), or endothelial cell 
migration and invasion during angiogenesis (Caldas et al., 2007). Here, 
survivin-∆Ex3 was characterized as an exclusively nuclear protein in tumor 
cells, whose stability in vivo and function in a DNA damage response were 
critically regulated by Chk2 phosphorylation (Reinhardt & Yaffe, 2009). This 
is consistent with an important role of post-translational modifications in 
controlling subcellular localization, protein-protein recognitions and 
modulation of apoptosis (Dohi et al., 2007), and cell division (Vong et al., 
2005), of the survivin pathway. 
Compelling evidence underscores a key role of Chk2 in a genomic 
integrity checkpoint after DNA damage. Activated via phosphorylation on 
Thr68 by the DNA damage sensor kinase, ataxia telangiectasia mutated 
(ATM), active Chk2 in turn phosphorylates a panoply of downstream targets 
implicated in checkpoint activation, cell cycle arrest, and apoptosis. In the 
case of survivin-∆Ex3, loss of Chk2 phosphorylation nearly completely 
suppressed γH2AX reactivity, a marker of unrepaired DNA damage (Bonner 
et al., 2008) important to recruit repair proteins to DNA foci (Paull et al., 
2000). The mechanistic requirements of this pathway have not been 
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completely elucidated, but data presented here indicate that Chk2-survivin-
∆Ex3 signaling is specific for DSB, is independent of an MRN complex 
(Lavin, 2007), and does not involve homologous-directed DNA repair. 
It is also clear that survivin-∆Ex3 does not directly regulate Chk2, as the 
overall levels of the kinase and its kinetics of activation in response to DNA 
damage were unaffected in the presence of phosphorylation-competent or –
defective surviving-∆Ex3. Taken together, these findings suggest that Chk2 
phosphorylation of survivin-
Ex3 may enhance sensing of DSB in tumor 
cells, i.e. via optimal γH2AX expression (Rodel et al., 2011). This pathway 
may be temporally important at the earliest stages after DNA damage, in light 
of the rapid turnover of Chk2 phosphorylated survivin-∆Ex3, and, similarly to 
a proposed role of survivin, may result in rapid recruitment of repair proteins 
to DSB foci, including DNA-PK (Reichert et al., 2011), or Ku70 (Jiang et al., 
2009). Functionally, this response would be expected to confer a survival 
advantage for tumor cells exposed to genotoxic stimuli. Consistent with this 
hypothesis, genome-wide bioinformatics studies presented here linked the 
expression of survivin-∆Ex3 to tumor progression, in vivo, in agreement with 
retrospective studies of patient cohorts (Koike et al., 2008, Nakano et al., 
2008), whereas, conversely, loss of Chk2 phosphorylation of survivin-∆Ex3 
impaired long-term clonogenic tumor cell survival after DSB. 
Aside from its tumor suppressive properties, which are inactivated by 
mutagenesis in a fraction of selected tumors (Motoyama & Naka, 2004), 
there has been considerable interest in exploiting the checkpoint function(s) 
of Chk2 for novel cancer therapeutics (Bolderson et al., 2009). Under the 
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definition of “checkpoint abrogation”, this strategy relies on small molecule 
antagonists of Chk2 (as well as Chk1) to prevent cell cycle arrest in response 
to DNA damage, thus triggering apoptosis, mainly by mitotic catastrophe 
(Jiang et al., 2009). However, the data presented here suggest that Chk2 
may play a more direct role in tumor progression (El Ghamrasni et al., 2011), 
potentially by exploiting multiple facets of the surviving pathway in 
transformed cells. In this context, the presence of activated Chk2 at the 
earliest stages of cellular transformation, in vivo (Gorgoulis et al., 2005, 
Bartkova et al., 2005), as exemplified here in the colorectal adenomato-
carcinoma transition, has been interpreted as a barrier to tumor development 
(Gorgoulis et al., 2005, Bartkova et al., 2005), but may also paradoxically 
promote the acquisition of pivotal cancer traits, including increased 
resistance of apoptosis via the release of survivin from its mitochondrial 
stores (Ghosh et al., 2008), and enhanced sensing of DNA damage via 
phosphorylation of survivin-∆Ex3 (this work). 
In summary, we have identified a novel link between Chk2 and an 
alternatively spliced survivin variant, ∆Ex3 in sensing DNA damage. In 
addition to further establishing the development of Chk2 inhibitors as a 
rational anticancer approach (El Ghamrasni et al., 2011), these data reinforce 
the general contribution of survivin family proteins to multiple aspects of 
tumorigenesis (Altieri, 2010), and validate therapeutic strategies aimed at 
globally disabling aberrant transcription of the surviving gene during tumor 
progression (Iwasa et al., 2008).
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This appendix contains a key of the most common acronyms and 
abbreviations used in this thesis. 
 
ATCC = American Type Culture Collection 
ATM = Ataxia-telangiectasia Mutated 
ATR = Ataxia-telangiectasia and Rad3 Related  
BER  = Base Excision Repair 
BIR = Baculoviral IAP Repeat 
BSA = Bovine Serum Albumin 
BRCA = Breast Cancer 
BTCC = Bladder Transitional Cell Carcinoma  
CARD = Caspase Recruitment Domain 
CDK = Cyclin-Dependent Kinase 
CHK1= Checkpoint Kinase 1 
CHK2= Checkpoint Kinase 2 
CHX = Cycloheximide 
DED = Death Effector Domain 
DMSO = Dimethyl Sulfoxide 
DSB = Double Strand Break 
EPR-1 = Effector Cell Protease Receptor-1  
EDTA = Ethylenediaminetetraacetic Acid 
Fas = Fibroblast-Associated protein 
FBS = Fetal Bovine Serum 
Flip = FADD-like interleukin-1-converting enzyme-inhibitory protein 
GG-NER= Global Genomic Nucleotide Excision Repair  
Hsp60 = Heat Shock Protein 60 
Hsp90 = Heat Shock Protein 90 
HR =            Homologous Recombination 
IAP = Inhibitor of Apoptosis Proteins 
LB = Loading Buffer 
LB medium =Luria-Bertani medium 
LRR = C-terminal Leucine-rich Repeat  
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MMR = Mismatch Repair 
MRI = Magnetic Resonance Imaging 
MSI = Microsatellite Instability 
NAIP = Neuronal Apoptosis Inhibitory Protein  
NER = Nucleotide Excision Repair  
NHEJ = Nonhomologous End-Joining 
NOD = Nucleotide-binding Oligomerization Domain  
ORF = Open reading frame 
PBS = Phosphate-Buffered Saline  
PCR = Polymerase Chain Reaction  
PVDF = Polyvinylidene Fluoride  
ROS = Reactive Oxygen Species  
RPA = Replication Protein A  
SDS = Sodium Dodecyl Sulfate 
siRNA = Small Interfering Ribonucleic Acid 
SSB = Single Strand Break 
TAE = TRIS-Acetate-EDTA 
TBE = Tris-Borate-EDTA 
TGS buffer = Tris-Glycine-SDS buffer 
TRAIL-R = TNF-Related Apoptosis-Inducing Ligand Receptor 
